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Chapter 1
Introduction
1.1 Overview
Patient care is a multifaceted, complex process. Clinical guidelines outline preferred
care practices, but because patients have unique needs, real-world practice can often differ
from guidelines. Patient care is also imperfect. Missed opportunities and errors occur
when the number of decision factors exceeds what is manageable for the care provider [1].
Nevertheless, computational tools including database systems and machine learning can
help make complex problems more manageable. To meet the demand for improved patient
care with technological solutions, it is necessary to design scientifically rigorous methods
that characterize the sufficiency of patient data, state of patient care, and opportunities
for improvement through the steps of data extraction, data analysis, and projections from
data.
Characterizing the current state of patient care, and finding opportunities for improve-
ment with computational tools requires sufficient patient data. Electronic health records
(EHRs) are digital stores of patient health records, and capture data including patient ap-
pointment times, medication events, and billing codes [2]. EHRs have many clinical bene-
fits including improved workflow and error reduction [3]. Additionally, the aggregated data
from EHRs is beneficial in a secondary use - scientific research.
Applying the data stored in EHRs to scientific research is challenging. EHR data are
often unstructured, and requires tools like Natural Language Processing (NLP) to transfer
unstructured text into structured data fields [4]. EHR data is often inconsistent, incom-
plete and prone to errors [5]. For example, instances like death and treatment transfer
are not always documented in the EHR. Therefore, terminal patient data does not inform
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on the patient’s current state. Furthermore, EHR data can follow different standards as
EHRs evolve, and across EHR systems, requiring reconciliation for longitudinal or cross-
institutional studies [6].
Although applying EHR data to research is challenging, it produces significant positive
contributions and healthcare advancements. Contributions include improved communica-
tion between patients and care providers [7], identification of missed diagnoses [8], reduced
errors [9] and improved patient care [10]. Advancements include genomic study enhance-
ment [11], clinical decision support [12], and data mining techniques [13]. EHR data are
an important factor for learning treatment practices and outcomes in the general patient
population, and for identifying opportunities for improvement.
EHR data analysis can characterize the state of patient care and learn opportunities
for improvement. State of patient care refers to the distribution of patients within a clin-
ical workflow. For example, patients requiring long-term follow-up are distributed across
’adherent to follow-up’ and ’loss to follow-up’ states. These states are further divided
into many other states, for example, ’receiving medication’ and ’not receiving medication’
states. Identifying an opportunity for improvement refers to 1) identifying a suboptimal
patient state and 2) determining a means to drive patient distribution away from that state.
If a patient’s state is ’receiving medication’ and ’reporting adverse symptoms,’ switching
their medication or treating their symptoms may move them to a ’no adverse symptom’
state.
One patient cohort in which we can learn the state of patient care and opportunities for
improvement is breast cancer patients undergoing long-term adjuvant endocrine therapy.
Adjuvant endocrine therapy is prescribed to breast cancer patients post surgery, chemother-
apy or radiation therapy to reduce risk of recurrence. Adjuvant endocrine therapy is recom-
mended for at least a five year duration to minimize risk of recurrence [14]. The adjuvant
endocrine therapy patient cohort is a model test-case to learn the state of patient care and
opportunities for improvement for several reasons. 1) Although clinical trials report rates
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of drug adherence and outcomes [15][16], there is little information on adjuvant endocrine
therapy in practice in the general breast cancer patient population. 2) Adjuvant endocrine
therapy has options for treatment, yielding many states in which patients are distributed.
3) Adjuvant endocrine therapy is a long-term treatment, during which patients move be-
tween states. Understanding the state of adjuvant endocrine therapy through EHR data,
and finding opportunities for improvement, may drive improved patient care in the adju-
vant endocrine therapy patient population.
This dissertation describes a novel set of methods to learn the state of patient care and
opportunities for improvement from EHR data. Our approach is divided into three aims: 1)
determine sufficiency of the data, 2) characterize the state of patient care, and 3) identify
opportunities for improvement. Sufficient data is necessary to characterize the state of
patient care, and characterizing the state of patient care is necessary to find opportunities
for improvement. To meet standards for scientific discovery, these methods are designed
to be reproducible and generalizable. These methods require common datatypes captured
by EHRs, which facilitates application to many EHR systems. Additionally, these methods
are founded at basic patient care and are extensible and customizable to other healthcare
domains. Generalizable and reproducible methods for learning the state of care and oppor-
tunities for improvement from EHR data will yield valuable information for many patient
cohorts, and drive better patient care in different settings.
1.2 Background
1.2.1 Electronic Health Record Systems
Electronic health records (EHRs) are digital stores of patient charts and healthcare in-
formation. Early EHR systems were introduced in the 1960s to allow clinicians quick
access to the most current versions of patient records [17]. As EHRs developed, they began
to provide clinical benefits that improve efficiency and quality of care such as increased
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guideline adherence, enhanced monitoring, and decreased medication errors [18]. Clinics
report fewer errors [19] and fewer costs [20] after transitioning from paper charts to an
EHR system. The well documented benefits helped incite Meaningful Use, a government
program that incentivizes EHR adoption and use [21] [22]. Through Meaningful Use, the
percent of physicians using EHRs rose from 44% in 2009 [23] to 83% in 2015 [24].
The widespread adoption of EHRs opens doors for a beneficial secondary use of patient
data: scientific research. Aggregated patient data allows for scientific analyses that give in-
sight into patient care and outcomes. Patterns learned from aggregated EHR data facilitate
clinical modeling [25] , data mining [26], and clinical decision support [27]. However, there
are challenges in drawing knowledge from EHR data. Data incompleteness, inaccuracies,
and inconsistencies are issues limiting secondary use studies [28] [29]. EHR data contains
patient health information on care received within the system that the EHR spans. Care
received in alternative EHR systems is not always shared, making patient health records
fragmented across systems. Additionally, EHR data may contain errors, non-standardized
data, and other issues which require data-cleaning and processing [5].
Vanderbilt University Medical Center (VUMC) is a group of hospitals and clinics that
has served over 3 million patients. VUMC’s EHR system has been evolving for close
to two decades. Table 1.1 lists VUMC’s EHR functionalities and the years they were
implemented. The implementation year denotes the year in which VUMC’s EHR began
capturing respective datatypes. The system captures a wide range of patient data including
billing codes, medications, and clinical communications. VUMC’s EHR data are extracted,
de-identified, and structured as part of the Synthetic Derivative (SD) for secondary use.
1.2.2 Adjuvant Endocrine Therapy
Hormone receptor-positive (HR+) breast cancers are uncontrolled growths dependent
on hormone intake (mainly estrogen intake) for proliferation [30]. Approximately 70% of
breast cancers are HR+ [31] and can be treated by preventing cells from binding estro-
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Table 1.1: Vanderbilt University Medical Center’s Electronic Health Record functionalities
and the years they were implemented
Function Implementation Year
Inpatient electronic clinical documentation 1997
Outpatient electronic clinical documenta-
tion
2001
Patient summary service (PSS) for medica-
tions
2003
Outpatient e-prescribing 2003 (Variable provider adoption over
time)
Inpatient order entry system 2004
Nursing Bar Code Medication Administra-
tion (AdminRx)
2007
gen. Endocrine therapy interferes with estrogen intake, and is prescribed as a treatment to
shrink HR+ tumors prior to surgery. More commonly, endocrine therapy is prescribed as
an adjuvant treatment to prevent cancer recurrence post treatment [32]. There are several
classes of adjuvant endocrine therapy drugs, and they prevent estrogen intake by different
mechanisms.
Selective estrogen-receptive modulators (SERMs) bind to estrogen receptors on cells
rendering them unreceptive to extracellular estrogen. SERMs do not lower the overall
levels of estrogen in the body, therefore are prescribed to pre- and peri- menopausal women.
Potential side effects of SERMs include but are not limited to hot flashes, and increased risk
of blood clots, cataracts, and uterine cancer. In the ATAC adjuvant trial, approximately 40%
of patients on SERMs reported hot flashes [15].
Aromatase inhibitors (AIs) prevent aromatase enzymes from converting androgen into
estrogen, which lowers the amount of estrogen in the body. AIs are effective when a pa-
tient’s main source of estrogen is androgen conversion, a characteristic of post-menopausal
women. Pre- and peri-menopausal woman must undergo natural or artificial menopause in
order for AIs to be effective.
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There are two types of AIs: steroidal and non-steroidal. Steroidal AIs form non-
reversible bonds with aromatase enzymes, while non-steroidal AIs form reversible bonds
and actively compete with androgen at binding sites. There is a lack of clinical trials fo-
cused on efficacy differences between steroidal and non-steroidal AIs, but because steroidal
AIs are purported to have androgenic effects, non-steroidal AIs are the recommended first
line AI treatment [33]. A common side effect of AIs is arthritis. A study by Henry et al
reported that out of a 97 breast cancer patients taking AIs, 44 experienced musculoskeletal
side effects, and 13 cases were severe enough for the patient to discontinue AI use [34].
Hot flashes, another common side effect of AIs, appeared in approximately 35% of patients
on AIs in the ATAC adjuvant trial [15].
In 1977, the Food and Drug Administration (FDA) approved the first endocrine therapy,
tamoxifen (a SERM), for use in metastatic hormone receptor positive breast cancer. In
1990, tamoxifen was approved for use in the treatment of early stage hormone receptor
positive breast cancer [35]. It was subsequently approved for use in prevention of breast
cancer in 1998 and for treatment of non-invasive ductal carcinoma in-situ (DCIS) in 2000.
Clinical studies on tamoxifen show that it consistently reduces risk for death and tumor
recurrence in HR+ breast cancer patients [36].
In 2002, the first aromatase inhibitor, anastrozole, was approved and demonstrated su-
periority over tamoxifen in the adjuvant treatment of post-menopausal woman with breast
cancer [15]. Subsequently, in 2005, letrozole and exemestane, two alternative aromatase
inhibitors, were also approved as adjuvant endocrine therapies in this setting.
In 1998, clinical guidelines recommended adjuvant endocrine therapy for a five year
duration post initial treatment[16]. Recent guidelines extended treatment duration up to
ten years in at-risk populations [14]. With extended timeframes for duration of treatment
and the growing number of available drug options, adjuvant endocrine therapy treatment
paths can vary across patients. Furthermore, clinical trials report varying rates of drug
termination (31-73%) [15][37], adverse events [34][38], and drug switches [39]. There is
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limited information on adjuvant endocrine treatment, including outcomes and follow-up,
in real-world settings.
Varying drug use and rates of adverse symptoms create complex states of patient care
for adjuvant endocrine therapy patients. Furthermore, since treatment is long-term, patients
can change states over the course of care. EHR data, including medications and billing
codes, from an adjuvant endocrine therapy patient can identify the patient’s state to the
extent of the EHR system. Sufficient data from a cohort of adjuvant endocrine therapy
patients can characterize the collective state of patient care, which in turn aids in identifying
opportunities for improvement.
1.2.3 Cohort Selection
Cohort selection for retrospective studies is mostly performed on an ad hoc basis. Co-
hort and data selection directly drives results and limitations. For example, building a co-
hort consisting of patients with perfect and complete EHR data biases results to possibly 1)
local patients and 2) patients diligent towards maintaining their health. Excluding patients
that are not local to the clinic’s location and are at higher risk for non-adherence fails to
represent real patient populations. Many retrospective studies require cohort selection, and
many studies depend on inter-study comparison of results when there is no gold-standard.
Methodology for cohort and data selection is useful in standardizing the cohort selection
process. Studies that use standard and consistent methodology for cohort selection reduce
variability in cohort selection that affects results. Comparing study results that follow the
same methodology for cohort selection has fewer limitations than comparing study results
that follow different cohort selection processes. Building a logical methodology for cohort
selection in retrospective EHR studies may benefit many secondary use studies.
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1.2.4 Machine Learning
Machine learning is a computational method to learn patterns from datasets. Learned
patterns take the form of a function that generalizes to new data points. Machine learning
is used to solve prediction problems where a vector maps to a specific outcome and there
is a desire to compute the correct outcome.
Machine learning is divided into supervised and unsupervised methods. Unsupervised
machine learning identifies structure or similarities among data [40]. Unsupervised ma-
chine learning can be abstract. There is no right answer to the underlying relationship of
the data, and there is no direct evaluation of the model’s performance. For example, given
a dataset of patient medications from both male and female patients, unsupervised ma-
chine learning may predict the females as one patient group and males as a different patient
group.
Supervised machine learning requires labeled data to train models [40]. Models should
generalize to correctly predict labels for new labeled data points. For example, given a
training dataset of patient medications mapped to a diagnosis that they treat, supervised
machine learning will build a function to best determine the diagnosis from the medica-
tions. Then, given a set of medications withheld from the training dataset, the function
will predict a diagnosis that the medications treat. Metrics like accuracy or area under the
receiver operating characteristic curve (ROC AUC) can evaluate model performance [40].
Accuracy is the percent of correct predictions out of all predictions. The AUC is the prob-
ability that a model will assign a higher probability prediction to a random positive class
vector than a random negative class vector.
Matching machine learning methods with clinical datasets yields predictive models
for clinical outcomes. Electronic health record systems are valuable data sources for fea-
ture vector construction for many prediction problems. For example, unsupervised learn-
ing methods can predict phenotypic patterns from EHR data that facilitate personalized
medicine [41]. Supervised machine learning methods can predict re-admittance rates from
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congestive heart failure patient EHR data [42]. Predicting outcomes in patient care is one
step toward patient care improvement. For example, predicting follow-up in the case of
long-term patients may identify features for patients that don’t follow-up. Informing clini-
cians that a patient may not follow-up allows them to coach the patient, or adjust treatment,
to improve follow-up rates.
1.2.5 Pre-Existing Efforts to Learn the State of Patient Care and Opportunities for Im-
provement
There are previous efforts to learn the state of patient care and opportunities for im-
provement in healthcare domains through data collection and statistical analysis. Two of
those efforts include The Surveillance, Epidemiology, and End Results (SEER) Program
of the National Cancer Institute, and The Patient-Centered Outcomes Research Institute
(PCORI).
The SEER Program compiles and distributes information on cancer statistics for the
purpose of informing the U.S. population on cancer burdens [43]. SEER began collecting
data in tumor registries in 1973. Since then, SEER expanded it’s tumor registry number
to cover a wide range of demographics. SEER currently holds data on approximately 28
percent of the US population, including 26 percent of African Americans, 38 percent of
Hispanics, 44 percent of American Indians and Alaska Natives, 50 percent of Asians, and
67 percent of Pacific Islanders. Data that SEER collects includes primary tumor sites, stage
at diagnosis, first course of treatment, vital status, etc. From the SEER registries, overall
cancer incidence, survival, and the first course of treatment can be summarized. Although
SEER data can characterize the state of care through survival and first course of treatment,
SEER data lacks other data that characterizes the complete state of care. For example,
SEER data does not include changes in treatment and patient side effects. In order to
characterize the complete state of care, additional data such as those in electronic health
records is necessary. Nevertheless, SEER data is a valuable resource for cancer research
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and are used by many researchers, clinicians, public health officials, and patients.
The PCORI organization is an independent non-profit group with the aim to deliver
information that drives desired health outcomes. PCORI grants fund patient-centered com-
parative clinical effectiveness research (CER). Their research mission is to help patients and
providers make informed healthcare decisions, improve healthcare delivery and outcomes,
by creating empirical research guided by patients, providers, and the broader healthcare
community [44]. PCORI breaks down their initiative into five priorities: 1) Assessment of
prevention, diagnosis, and treatment options, 2) Improving healthcare systems, 3) Commu-
nication and dissemination research, 4) Addressing disparities, and 5) Accelerating patient-
centered outcomes research and methodological research. PCORI’s interests align with
learning the state of patient care and opportunities for improvement, and PCORI grants
fund research germane to the methods in this dissertation.
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Chapter 2
Research Statement
This dissertation constructs methodology that determines the sufficiency of patient
data, characterizes the state of patient care, and identifies opportunities for improvement
from electronic health record (EHR) data. The methods are applied to an adjuvant en-
docrine therapy patient cohort treated at Vanderbilt University Medical Center (VUMC)
using VUMC’s EHR system. Chapter 3 describes steps to determine the sufficiency of
EHR data availability, and the role of data availability in data selection and interpreting
results (i.e. inferring failure to follow-up vs treatment transfer). Chapter 4 describes sta-
tistical and visualization methods to learn the state of patient care. We measure drug use,
frequencies of adverse symptoms, and disease recurrence. Last, chapter 5 describes steps
to explore opportunities for improvement in patient care with machine learning. We look
for signals to indicate failure to follow-up at VUMC for five-years (the minimum recom-
mended treatment duration). The complete workflow is shown in Figure 2.1.
2.1 Aims
2.1.1 Aim 1: Determine sufficiency of the data
Data sufficiency is the availability and limitations of data for research. For data to be
sufficient for a long-term patient cohort analysis, data must span the timeframe for which
treatment occurs. Data should begin at or before a minimum time prior to data collection,
and data should persist throughout the timeframe. However, when data are inconsistent
or missing, they may be sufficient with limitations. Rather than including or excluding
all imperfect data, we can weight data importance based on availability of alternative data
types. Determining data sufficiency is challenging due to characteristics of the EHR. EHR
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Determine	  Suﬃciency	  of	  
Data	  for	  Long-­‐Term	  Cohort	  
Studies	  
	  
Tasks:	  
1)  Measure	  availability	  
2)  Build	  metrics	  to	  facilitate	  
cohort	  selecCon	  based	  
on	  availability	  
3)  Generalize	  methodology	  
for	  long-­‐term	  cohort	  
selecCon	  in	  other	  
domains	  
	  
	  
Characterize	  the	  State	  of	  
PaCent	  Care	  
	  
	  
Tasks:	  
1)  Deﬁne	  all	  possible	  states	  
of	  adjuvant	  endocrine	  
therapy	  care	  
2)  Determine	  paCent	  
inclusion	  in	  each	  state	  
from	  data	  
3)  Apply	  staCsCcal	  &	  
visualizaCon	  methods	  to	  
characterize	  paCent	  care	  
	  
IdenCfy	  New	  OpportuniCes	  
for	  Improvement	  in	  
	  PaCent	  Care	  
	  
Tasks:	  
1)  IdenCfy	  controllable	  and	  
uncontrollable	  factors	  
aﬀecCng	  care	  outcomes	  
2)  Frame	  a	  classiﬁcaCon	  
problem	  using	  features	  
and	  labels	  from	  data	  
3)  	  Apply	  machine	  learning	  
methods	  to	  predict	  
classiﬁcaCons	  
Aim	  1	   Aim	  2	   Aim	  3	  
Electronic	  Health	  Records	  At	  Vanderbilt	  University	  Medical	  Center	  
Breast	  Cancer	  PaCents	  	  
Figure 2.1: Complete workflow of the dissertation for learning the state of patient care
and opportunities for improvement from EHR data. All work is completed from electronic
health record data from breast cancer patients treated at Vanderbilt University Medical
Center.
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adoption and functionality implementation occurs at different rates, which leads to differing
data availability. Patient data spans the timeframe of the patient’s return visits, which may
not always be the optimal timeframe. Determining data sufficiency allows for more reliable
data, and accurate interpretation of results. Tasks to determine data sufficiency include 1)
measuring data availability, 2) building metrics based on data availability to facilitate data
selection, and 3) generalizing the methodology for application to other health care domains.
2.1.2 Aim 2: Characterize the state of patient care
The state of patient care is the distribution of patients across a clinical workflow. Char-
acterizing the state of patient care from EHR data allows for insight on treatment patterns
in the real-world setting. Information on the state of patient care in real-world setting can
give clinicians and patients realistic expectations about treatment, and help them make de-
cisions regarding care. For example, in an adjuvant endocrine therapy patient population,
we understand that patients often discontinue treatment, or change their treatment plan, but
the rate of those occurrences and the timeframe in which they happen are unmeasured. If
and patient and provider learn that patients using a specific drug change their treatment
plan at a certain time, the patient and provider can expect and plan for that event. The
current state of patient care is challenging to characterize because it requires many aggre-
gated structured statistics and data types like appointment times, medication events and
billing codes. Analyzing the state of patient care is particularly challenging in long-term
cohorts due to changes in data availability and data types over time. Tasks to characterize
the state of patient care include: 1) mapping the possible states of care, and 2) determining
distribution of patients across states from EHR data.
2.1.3 Aim 3: Identify new opportunities to improve patient care
Opportunities for patient care improvement are signals in the EHR data that indicate
a patient is in a suboptimal patient state. Signals can facilitate patient care improvement
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suggest a means of shifting patient distribution away from the suboptimal state into a more
favorable state. For example, patients in a state with adverse side effects may be moved
into a state without adverse side effects by 1) treating their side effects or 2) altering their
medications. Finding signals for patient care improvement is challenging because it re-
quires large amounts of structured data and many different data types. Tasks to identify
new opportunities to improve patient care include 1) identifying controllable and uncon-
trollable factors affecting care outcomes, 2) framing a classification problem using features
and labels from EHR data, and 3) applying machine learning methods to identify signals
for patient care improvement.
2.2 Value of the Work
2.2.1 Biomedical Informatics Techniques
Technical achievements of this work include measuring the completeness and limita-
tions of VUMC’s EHR data for characterizing and improving breast cancer treatment. Our
methods and metrics facilitate secondary use of VUMC’s EHR data in breast cancer stud-
ies. Additionally, our exploration of machine learning applications to EHR data support
machine learning as a useful tool to improve breast cancer treatment.
This work enhances biomedical informatics techniques by defining tasks necessary to
learn the state of patient care and opportunities for improvement. We address limitations
and steps to improve methodology. For example, we promote health information exchange
and the need for additional data sources to enhance the understanding of healthcare prob-
lems. Additionally we took steps to understand the generalizability of our methods to other
healthcare domains.
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2.2.2 Clinical Knowledge
This work benefits the breast cancer clinicians and patients by providing an empiri-
cal summary of adjuvant endocrine therapy treatment at VUMC. Summary statistics on
adjuvant endocrine therapy hallmarks, including drug switches, drug discontinuation, and
recurrences, provide realistic expectations for treatment at VUMC. Realistic expectations
translate into better planning for care. Furthermore, predicting follow-up informs clinicians
of the significant features that indicate whether a patient will complete adjuvant endocrine
therapy at VUMC, which facilitates planning for continuing care.
The broader value of this work benefits the biomedical informatics research commu-
nity. Our methods to determine data sufficiency, characterize the state of patient care, and
identify opportunities for improvement among adjuvant endocrine therapy patients act as a
scaffold to generalize and extend to other healthcare domains. This work defines necessary
tasks to learn the state of patient care and opportunities from improvement.
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Chapter 3
Aim 1: Determine Sufficiency of the Data
3.1 Overview
This chapter aims to determine the sufficiency of Electronic Health Record data to learn
the state of patient care and opportunities for improvement. The text is an extended version
of an academic journal article titled Evaluating EHR Data Availability for Cohort Selec-
tion in Retrospective Studies published at the IEEE International Conference on Health
Informatics. The article describes metrics for data availability among adjuvant endocrine
therapy patients treated at Vanderbilt University Medical Center. We address the rise of
data population as VUMC’s EHR evolves, data persistence over time, and strategies to
handle missing data. Additionally, we generalize our methods for applications of EHR
data extraction in other healthcare domains. Once data completeness and limitations were
properly defined, we tested our methods to select a cohort of adjuvant endocrine therapy
patients for a longitudinal study on five-year follow-up.
The methods in this chapter are related to measurements of exposure and outcomes in
the field of statistics. Exposure and outcome are observable traits with a relationship such
that exposure affects the outcome [45]. In this chapter, data availability is the exposure
variable, and data persistence over some time is the outcome. As time periods for data
availability increases, the probability of data persistence decreases.
This chapter shows the impact of data sufficiency on secondary use of EHR data and
contributes generalized methods for data selection based of EHR data sufficiency. The
main finding of this study are 1) data sufficiency can drive data selection for secondary use
studies, 2) data sufficiency metrics can serve as weights for missing data points, and 3) and
data sufficiency affects secondary use study results.
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3.2 Introduction
Retrospective studies with longitudinal medical data can answer questions about med-
ication compliance, adverse drug events, and therapeutic efficacy in a population. Sources
for robust longitudinal medical data include Electronic Health Record (EHR) systems,
billing systems, and registries. EHRs collect various medical data-types for patients over
time including billing codes, medication events, and diagnoses. However, there are several
challenges to using longitudinal EHR data in retrospective studies.
Retrospective studies require a patient cohort with reliable longitudinal data, including
accurate start and end points. Due to characteristics of the EHR, it is often unclear when
reliable data begins and ends. Evolving EHR functionality and disparate provider adoption
leads to discrepancies in EHR data population. For example, Vanderbilt University Medical
Center (VUMC) initially implemented its EHR in the inpatient setting prior to the outpa-
tient setting, resulting in temporally more complete data for patients admitted as inpatients.
Additionally, EHRs infrequently document patients exiting the healthcare system, leaving
an indeterminate end date for patient EHR data. Applying longitudinal EHR data in retro-
spective studies requires 1) determining when past data becomes consistently available and
2) determining when patient data ends.
One strategy for using longitudinal EHR data in a retrospective study is selecting a pa-
tient cohort with data that 1) begins after a threshold for consistent data availability and
2) persists for a specified timeframe measured through records and clinical activity in the
EHR. This can be achieved by defining data availability metrics, and applying the metrics
to maximize the amount of reliable data and minimize the amount of ambiguous data in-
cluded in the study. Currently, patient cohort selection for retrospective studies is done on
an ad hoc basis. While there have been many studies using billing codes and medication
events extracted from the EHR [46] [47] [48], and many studies using weighted EHR data
[49] [50], to our knowledge there have been no studies applying EHR data availability to
retrospective study cohort selection. We sought to improve cohort selection by creating
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a generalizable heuristic based on EHR data availability. We 1) created data-driven met-
rics for longitudinal EHR data availability, 2) utilized the metrics for data restriction and
weighting in a cohort selection heuristic, and 3) tested our heuristic on a cohort of stage I-III
breast cancer patients for a retrospective study on adjuvant endocrine therapy adherence.
3.3 Background
There are many real-world scenarios that make identifying longitudinal cohorts from
EHR data challenging. Differing timeframes for EHR adoption and added functionality
results in staggered data availability. VUMC’s EHR system has been evolving for close
to two decades. Inpatient electronic clinical documentation began in 1997, and outpatient
electronic clinical documentation began in 2001. The patient summary service (PSS) for
medications and outpatient e-prescribing began in 2003, although with variable provider
adoption over time. The inpatient order entry system began in 2004, and Nursing Bar Code
Medication Administration (AdminRx) began in 2007. As a result, the available data for
patients changed over time in direct relation to added EHR functionality. Furthermore, lack
of documentation on patients leaving the EHR system result in ambiguous data termination.
Reasons that a patient may leave the healthcare system include 1) death, 2) completion of
care, 3) transfer of care to another institution and 4) discontinuation of care. Although
death events can be clearly documented in most EHRs, many patients die outside of the
hospital. As a result, death events are not consistently communicated back to the managing
healthcare system and thus not documented in the EHR. Alternative resources for ascer-
taining death for a large population are typically required [51]. Likewise, when a patient
completes their treatment and is discharged from active care, there is limited structured
documentation in the EHR to indicate this plan. Finally, when patients transfer their care
to a different facility, the managing provider may never be notified. A request for outside
medical records may be the only indication of such a transition, but there is no place to
document this in a structured way in current EHR systems.
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Despite data inconsistencies, EHRs are a valuable data source for longitudinal retro-
spective studies. VUMC’s Synthetic Derivative is a data source of de-identified health
records from over 2 million patients [52]. The Synthetic Derivative includes over 200 mil-
lion billing codes in the form of ICDs and CPTs, and over 400 million medication events de-
rived from medication lists and clinical notes with the natural language processing method,
MedEx [4]. Additionally, the Synthetic Derivative also includes a tumor registry that con-
tains detailed diagnosis, staging and treatment information for over 90,000 patients with
cancer linked to their electronic health record.
One retrospective study requiring longitudinal medical data is an analysis on adjuvant
endocrine therapy adherence. Adjuvant endocrine therapy is prescribed to hormone recep-
tor positive breast cancer patients to prevent tumor recurrence. Women who complete five
years of the adjuvant endocrine therapy drug, Tamoxifen, have a significantly lower risk
of breast cancer recurrence and mortality than women who only complete 1-2 years [53].
Unfortunately, drug side effects like hot flashes, arthritis pains, mood disturbances, and
bone loss often make it difficult for patients to complete five years of treatment [54]. In
the ATAC clinical trial, approximately 85% of tamoxifen-treated patients adhered to five
years of treatment [15]. Studies on adherence in the general patient population report lower
and varying rates. One study reports 69% five-year adherence through patient interviews
during treatment [55]. This study does not depend on EHR data availability, but patient
interviews are not always viable for retrospective studies. An alternative study reports 49%
five-year adherence from automated pharmacy records of hormonal therapy prescriptions
and refills [56]. Patients in the study were censored at date of dis-enrollment in the system
(among other reasons), which may be underreported. The study does not seek alterna-
tive data availability in the EHR to confirm patient enrollment, leaving an opportunity to
improve results.
Applying EHR data availability metrics to cohort selection for a retrospective adjuvant
endocrine therapy adherence study can optimize data utility and lead to more accurate
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Figure 3.1: Generalized cohort selection heuristic employing EHR data availability metrics
Generalized Heuristic for Patient Cohort Selection in Retrospective EHR
Studies
• Select patient population with desired medical event
(i.e. adjuvant endocrine therapy patients)
• Set desired length of longitudinal data and data intervals
(i.e. 5 years, 12 month intervals)
• Set date restrictions to data based on the selected medical event
(i.e. clinical guidelines began recommending adjuvant endocrine therapy
for at least 5 years in 1998)
• Set restrictions based on data availability metrics
Set threshold for data availability
Set weighting parameter (include/exclude)
• Select cohort meeting all rescrictions
• Perform analysis (if necessary, recalibrate and repeat)
results. Furthermore, a generalized heuristic employing EHR data availability metrics can
facilitate cohort selection for a multitude of longitudinal retrospective studies.
3.4 Methods
Our objective is to create a heuristic for selecting cohorts with sufficient longitudinal
EHR data. The heuristic should consider when data becomes consistently available, and
adjust for the rate at which patients leave the EHR system. To construct this heuristic, we
define data availability metrics that determine the start and end of EHR data per patient,
and then use these metrics in rules for cohort selection. We applied this heuristic to a breast
cancer cohort for an adjuvant endocrine therapy adherence analysis.
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Table 3.1: Selected Adjuvant Endocrine Therapy Drugs
Generic Name Other Names Drug Class Year of FDA
approval for
metastatic
therapy
Year of FDA
approval for
adjuvant ther-
apy
Anastrozole Arimidex Non-steroidal
AI
2000 2002
Exemestane Aromasin Steroidal AI 2005 2005
Letrozole Femara Non-steroidal
AI
2005 2005
Tamoxifen Nolvadex SERM 1977 1990
3.4.1 Data extraction
Data was collected from the VUMC Synthetic Derivative and includes 1) billing codes
(ICDs, CPTs), which depict any billable event recorded in the EHR system, 2) medication
event data, which depict drug information documented in the EHR for the patient, and 3)
tumor registry data, which is populated for patients diagnosed at VUMC or receiving the
majority of their treatment at VUMC. Tumor registry data includes the cancer diagnosis
site (e.g. breast) and histology (e.g invasive ductal carcinoma), date of diagnosis, cancer
stage, and vital status including date of last known contact and date of death. The adjuvant
endocrine therapy drugs identified for our adherence analysis are listed in Table 3.1.
3.4.2 Metrics
To determine when data are consistently available, we first summarized the growth of
billing code, medication event, and tumor diagnosis data points in the EHR for all patients
and for the subset of patients diagnosed with stage I-III breast cancer.
Second, we calculated the percentage of patients who had a particular data type (billing
code, medication event, or adjuvant endocrine therapy medication event) available in a
particular twelve-month interval before or after their diagnosis year. Specifically, given a
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year y in which a clinical event begins, and the ith 12-month interval post clinical event, let
cohort Cyi be the n patients with the clinical event in year y with no recorded death before
interval i. Then, the number of patients, in Cyi with EHR data in interval i is:
D(Cyi) =
c=n
∑
c=0

0 if /0 datapoints in i
1 if ≥ 1 datapoints in i
(3.1)
Finally, the percentage of data available is calculated as the number of patients with
greater than zero data points during the 12 month interval divided by all patients in the
given diagnosis-year group.
Data Availability(Cyi) =
D(Cyi)
n (3.2)
Patients were censored from subsequent intervals if they had a reported death in the
tumor registry.
The change in data availability from a given year over subsequent 12 month intervals
measures how long data are consistently available. A rise in data availability denotes that
previous data was not substantially populated. A drop in data availability denotes patients
leaving the EHR system. For example, if we measure 95% data availability for breast
cancer patients diagnosed in 2006, and 73% data availability in that population post five
years, than we know 22% of those patients left the EHR system in that timeframe, whether
it be from transferred treatment or discontinued treatment etc. We use these data availability
measures as weights for patients in the cohort (described in subsection 3.4.4).
3.4.3 Visualization
To visualize our data availability measures, we built a series of heat maps. Availability
metrics are calculated for patients grouped by initial diagnosis year and normalized on the
initial diagnosis year. Each measure in the heatmap is the percentage of data available
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calculated by equation 3.2. Patients were censored from subsequent intervals if they had a
reported death in the tumor registry.
3.4.4 Cohort Creation Heuristic
We defined a heuristic that employs cohort restrictions specific to adjuvant endocrine
therapy and EHR data availability metrics. For patients to be included in the cohort, their
date of diagnosis must be equal or later than 1998, when clinical guidelines began to rec-
ommended five years of adjuvant endocrine therapy [16], and the date of diagnosis must be
equal to or later than dates where 90% of a given EHR data-type is populated. Our desired
study timeframe is five years, and we chose 12-month intervals for which to extract data
points since patients on adjuvant endocrine therapy typically have follow-up appointments
at least every 6 months for the first five years. If a patient does not have an instance of a
given data type for a 12-month interval, we infer that their longitudinal data has ended.
Given our available data-types (billing codes and medication events) and data avail-
ability metrics, we created six separate cohorts for adjuvant endocrine therapy adherence
analyses Table 3.2. The cohorts are restricted by availability of data types or combination
of data types, and weighted by data persistence. Data type availability restrictions require
that patients have greater than zero data points of a specific data type per 12-month interval.
Data persistence, defined as the data availability in the ith year, can be used as a weight to
estimate a patient’s persistence in treatment, and allows for an upper and lower bound on
patients included in the cohort.
We can propose two strict assumptions for adjuvant endocrine therapy patients with
discontinued data prior to five years: 1) all are non-adherent to adjuvant endocrine therapy,
or 2) all are continuing treatment elsewhere. We know that the true explanation lies between
these extremes. So, we create an upper bound cohort, where we exclude patients with a
missing data point for a 12-month interval, and a lower bound cohort, where we assume
all patients with a missing data point for a 12 month interval are non-adherent at the rate
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Table 3.2: Cohort Restrictions for Adjuvant Endocrine Therapy Analysis
No Weighting
(Exclude Patients with
Missing Data)
Weight Patients
with Missing Data
Restrict on Billing
Code Availability
Cohort 1
Upper Bound
Cohort 1
Lower Bound
Restrict on Medication
Event Availability
Cohort 2
Upper Bound
Cohort 2
Lower Bound
Restrict on Both
Billing Code and
Medication Event
Availability
Cohort 3
Upper Bound
Cohort 3
Lower Bound
of data availability in that interval. We believe this is a reasonable lower bound because
this represents a natural rate of patients leaving the system. Determining adherence within
these different cohorts allows for a range of adherence rates and a margin of error.
We generalized our steps for adjuvant endocrine therapy cohort selection so they may
be employed toward cohort selection in a multitude of retrospective studies requiring lon-
gitudinal EHR data (Figure 3.1).
3.4.5 Adjuvant Endocrine Therapy Adherence Analysis
We determined the completion rate each year for five years of adjuvant endocrine ther-
apy in each of the six patient cohorts. The rate of completion is the number of patients with
at least one adjuvant endocrine therapy medication event documented in the EHR per year
divided by the total number of patients in the cohort.
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Table 3.3: Summary of data availability from VUMC EHR.
Data source Tumor Reg-
istry
Billing data Any medica-
tion event
Endocrine therapy
medication event
Dates data
available in
source
1960-2014 1987-2014 1984-2014 1991-2014
Count of pa-
tients with data
available in
source
84857 2.2 million 777000 8534
Count of data
elements avail-
able in source
90000 167 million 363 million 690000
Year data first
available for
breast cancer
cohort
1964 1987 1988 1991
Count of stage
I-III breast
cancer patients
with data in
source
5824 5240 3492 1945
Count of data
elements avail-
able for cohort
in source
5824 2 million 8 million 401000
3.5 Results
3.5.1 Metrics and Visualization
The rise in data availability of billing codes, medication events, and tumor registry
diagnoses within VUMC’s EHR for both the general population and the subset of stage I-
III breast cancer patients are shown in Figure 3.2. Both EHR utilization and VUMC patient
volumes increased during the forty-year period. Summary statistics for data availability are
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in in Figure 3.3. We identified 5824 patients with stage I-III breast cancer in the VUMC
Tumor Registry beginning in 1964. The first billing data became available for this patient
cohort in 1987, the first medication events in 1988, and the first endocrine therapy events
in 1991. Although tumor registry data predates billing and medication event data by over
20 years, 59% percent of all patients in in the tumor registry and 60% of stage I-III breast
cancer patients in the tumor registry had all three data types available.
The percent of data population in the EHR for billing codes, medication events, and ad-
juvant endocrine therapy medication events for stage I-III breast cancer patients are shown
as heatmaps in Figures 3.3, 3.4, and 3.5. In each heatmap, the diagnosis year is represented
along the y-axis, and 12-month intervals are represented along the x-axis. Y-1 is 12 months
prior to the diagnosis date, Y0 is 12 months after the diagnosis date, and so on. The values
in the heatmap are the percentages of patients in a given group with greater than zero data
points for that term. Ideally, all patients would have billing codes and medication events
during their year of diagnosis, resulting in 100% data population for all diagnosis years in
the Figure 3.3 and Figure 3.4 Y0 columns. Lesser percentages denote unpopulated data in
the EHR. Patients who receive adjuvant endocrine therapy are those with hormone recep-
tive positive breast cancers, which make up approximately 70-80% of breast cancers [31].
Therefore, data population in Figure 3.5 Y0 column is ideally 70-80%, and extend through
Y4 column for five years of therapy adherence.
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Figure 3.2: Counts of billing codes, medications and tumor registry patients by year in the
VUMC EHR for all patients and for the subset of stage I-III breast cancer patients.
Y"1 Y0 Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10
1990 0.00 0.01 0.00 0.00 0.10 0.49 0.57 0.54 0.66 0.65 0.60 0.50
1991 0.01 0.05 0.01 0.05 0.54 0.51 0.52 0.55 0.50 0.56 0.45 0.40
1992 0.00 0.06 0.11 0.47 0.66 0.65 0.58 0.55 0.50 0.45 0.41 0.46
1993 0.00 0.15 0.63 0.64 0.63 0.63 0.60 0.61 0.54 0.55 0.55 0.52
1994 0.16 0.71 0.65 0.65 0.63 0.57 0.56 0.52 0.45 0.45 0.51 0.51
1995 0.46 0.86 0.72 0.73 0.68 0.66 0.67 0.58 0.56 0.43 0.43 0.44
1996 0.38 0.82 0.78 0.74 0.67 0.61 0.61 0.55 0.51 0.49 0.47 0.46
1997 0.31 0.87 0.73 0.65 0.60 0.58 0.52 0.48 0.44 0.40 0.43 0.46
1998 0.45 0.90 0.85 0.77 0.74 0.69 0.66 0.60 0.64 0.64 0.65 0.62
1999 0.39 0.93 0.88 0.80 0.75 0.69 0.70 0.65 0.62 0.58 0.55 0.52
2000 0.39 0.95 0.82 0.78 0.76 0.72 0.70 0.66 0.62 0.57 0.54 0.50
2001 0.45 0.94 0.81 0.76 0.67 0.66 0.63 0.62 0.62 0.52 0.50 0.47
2002 0.44 0.94 0.87 0.74 0.72 0.67 0.68 0.61 0.64 0.56 0.56 0.57
2003 0.46 0.93 0.86 0.86 0.79 0.71 0.71 0.72 0.67 0.68 0.67 0.63
2004 0.44 0.94 0.87 0.82 0.78 0.75 0.72 0.69 0.68 0.67 0.65 0.44
2005 0.42 0.94 0.85 0.77 0.75 0.73 0.68 0.66 0.64 0.60 0.45
2006 0.41 0.95 0.87 0.84 0.77 0.73 0.75 0.74 0.72 0.46
2007 0.45 0.97 0.91 0.83 0.74 0.77 0.78 0.74 0.54
2008 0.51 0.97 0.87 0.81 0.80 0.79 0.73 0.55
2009 0.50 0.96 0.88 0.86 0.81 0.78 0.60
2010 0.44 0.94 0.88 0.86 0.86 0.66
2011 0.34 0.95 0.90 0.86 0.57
2012 0.48 0.96 0.92 0.68
2013 0.45 1.00 0.74
2014 0.59 0.97
Figure 3.3: BILLING CODES: Percentage of breast cancer stage I-III patients with greater
than zero billing codes within 12-month intervals surrounding their diagnosis date. Diag-
nosis date is represented along the y-axis and 12-month intervals are represented along the
x-axis. Y-1 is the 12-month period prior diagnosis date, Y0 is the 12-month period after
diagnosis, and so on.
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Y"1 Y0 Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10
1990 0.00 0.04 0.20 0.09 0.16 0.19 0.14 0.34 0.39 0.42 0.36 0.44
1991 0.01 0.19 0.18 0.14 0.17 0.18 0.29 0.32 0.30 0.29 0.34 0.32
1992 0.05 0.17 0.13 0.16 0.17 0.24 0.27 0.28 0.26 0.31 0.30 0.43
1993 0.05 0.30 0.17 0.17 0.30 0.39 0.40 0.40 0.44 0.40 0.51 0.51
1994 0.06 0.50 0.30 0.48 0.48 0.47 0.39 0.40 0.43 0.43 0.44 0.48
1995 0.05 0.50 0.43 0.53 0.50 0.50 0.51 0.46 0.48 0.44 0.44 0.43
1996 0.09 0.69 0.62 0.53 0.53 0.48 0.48 0.43 0.42 0.44 0.43 0.40
1997 0.17 0.84 0.61 0.52 0.55 0.53 0.48 0.43 0.41 0.37 0.39 0.42
1998 0.24 0.86 0.72 0.71 0.65 0.61 0.61 0.57 0.57 0.60 0.64 0.64
1999 0.24 0.89 0.79 0.67 0.68 0.67 0.69 0.65 0.61 0.56 0.54 0.55
2000 0.30 0.90 0.73 0.73 0.73 0.67 0.67 0.65 0.63 0.59 0.54 0.54
2001 0.29 0.89 0.75 0.74 0.61 0.60 0.60 0.60 0.59 0.53 0.52 0.48
2002 0.38 0.93 0.85 0.74 0.71 0.68 0.68 0.63 0.65 0.64 0.59 0.60
2003 0.40 0.91 0.82 0.84 0.79 0.72 0.72 0.72 0.71 0.68 0.67 0.64
2004 0.40 0.94 0.86 0.82 0.77 0.73 0.72 0.70 0.68 0.66 0.67 0.53
2005 0.38 0.93 0.82 0.77 0.73 0.75 0.70 0.66 0.66 0.61 0.51
2006 0.37 0.93 0.86 0.85 0.78 0.77 0.76 0.73 0.75 0.64
2007 0.41 0.97 0.92 0.85 0.82 0.79 0.79 0.75 0.66
2008 0.48 0.96 0.89 0.83 0.81 0.82 0.77 0.66
2009 0.48 0.97 0.90 0.86 0.84 0.80 0.72
2010 0.44 0.94 0.90 0.88 0.87 0.78
2011 0.37 0.96 0.91 0.89 0.74
2012 0.52 0.99 0.93 0.78
2013 0.52 1.00 0.85
2014 0.61 0.98
Figure 3.4: MEDICATION EVENTS: Percentage of breast cancer stage I-III patients with
greater than zero medication events within 12-month intervals surrounding their diagnosis
date. Diagnosis date is represented along the y-axis and 12-month intervals are represented
along the x-axis. Y-1 is the 12-month period prior to diagnosis date, Y0 is the 12 month
period after diagnosis, and so on.
Y"1 Y0 Y1 Y2 Y3 Y4 Y5 Y6 Y7 Y8 Y9 Y10
1990 0.00 0.00 0.00 0.00 0.05 0.07 0.03 0.14 0.18 0.18 0.15 0.08
1991 0.00 0.00 0.00 0.02 0.03 0.05 0.15 0.22 0.20 0.26 0.15 0.16
1992 0.00 0.01 0.00 0.04 0.06 0.19 0.23 0.17 0.11 0.09 0.07 0.15
1993 0.00 0.03 0.04 0.11 0.28 0.34 0.32 0.28 0.29 0.29 0.26 0.25
1994 0.00 0.03 0.09 0.32 0.40 0.38 0.36 0.35 0.31 0.27 0.26 0.26
1995 0.01 0.08 0.20 0.33 0.31 0.30 0.31 0.25 0.25 0.26 0.23 0.19
1996 0.00 0.35 0.44 0.40 0.36 0.33 0.29 0.26 0.24 0.21 0.24 0.24
1997 0.02 0.61 0.50 0.44 0.42 0.44 0.38 0.32 0.28 0.28 0.28 0.26
1998 0.02 0.71 0.60 0.52 0.47 0.44 0.43 0.39 0.38 0.38 0.35 0.33
1999 0.01 0.72 0.57 0.46 0.47 0.43 0.42 0.35 0.35 0.30 0.29 0.30
2000 0.00 0.70 0.56 0.47 0.45 0.44 0.42 0.35 0.37 0.33 0.30 0.28
2001 0.01 0.65 0.48 0.45 0.37 0.37 0.35 0.31 0.31 0.27 0.22 0.24
2002 0.02 0.71 0.54 0.47 0.47 0.46 0.46 0.38 0.42 0.41 0.39 0.38
2003 0.00 0.68 0.52 0.51 0.50 0.48 0.47 0.44 0.41 0.38 0.39 0.36
2004 0.02 0.67 0.57 0.55 0.53 0.51 0.49 0.47 0.47 0.42 0.42 0.35
2005 0.00 0.59 0.52 0.49 0.47 0.49 0.49 0.43 0.42 0.39 0.34
2006 0.01 0.59 0.53 0.52 0.48 0.51 0.51 0.47 0.47 0.42
2007 0.02 0.66 0.63 0.58 0.57 0.59 0.57 0.54 0.49
2008 0.02 0.68 0.61 0.55 0.56 0.57 0.53 0.46
2009 0.00 0.63 0.58 0.56 0.55 0.54 0.48
2010 0.02 0.66 0.62 0.61 0.59 0.54
2011 0.02 0.67 0.62 0.62 0.58
2012 0.01 0.71 0.67 0.62
2013 0.01 0.76 0.71
2014 0.04 0.74
Figure 3.5: ADJUVANT ENDOCRINE THERAPY: Percentage of breast cancer stage I-III
patients with greater than zero adjuvant endocrine therapy medication events (medications
listed in Table 1) within 12 month intervals surrounding their diagnosis date. Diagnosis
date is represented along the y-axis and 12-month intervals are represented along the x-
axis. Y-1 is the 12-month period prior to diagnosis date, Y0 is the 12 month period after
diagnosis, and so on.
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3.5.2 Adjuvant Endocrine Therapy Cohort Selection
The cohort restrictions imposed on stage I-III breast cancer patients in the VUMC tu-
mor registry are described in Figure 3.6. We required that 1) patients be diagnosed between
1998 and 2010, and 2) patients must have at least one adjuvant endocrine therapy medica-
tion event. Restrictions imposed though our heuristic required that 1) patient data begins
at or after 90% availability for a given data-type and 2) data persists each year up to five
years measured by existence of greater than 0 data points per year. We found 1710 patients
with appropriate billing code availability. 1711 patients with appropriate medication event
availability, and 1627 patients with both appropriate billing code and medication event
availability.
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Figure 3.6: Patient cohort selection flowchart.
3.5.3 Adjuvant Endocrine Therapy Adherence
Our adjuvant endocrine therapy adherence analysis determines the number of patients
with at least one adjuvant endocrine therapy medication event per year, beginning from
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their first adjuvant endocrine therapy drug up to five years, divided by the total number of
patients in the given cohort. Adherence rates per cohort are graphed in Figure 3.7. The five-
year upper bound completion rate is between 74 and 78% and the five-year lower bound
completion rate is between 55 and 57% across the respective cohorts.
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Figure 3.7: Upper and lower bound adjuvant endocrine therapy adherence through five
years in cohorts selected with the EHR data availability heuristic (Cohorts described in
Table II).
3.6 Discussion
Electronic health record (EHR) systems are a valuable source for longitudinal medical
data, but applying that data to retrospective studies requires determining accurate data start
and endpoints. To determine data start and endpoints, we constructed data availability
metrics using data from VUMC’s EHR, a system that has been evolving for nearly two
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decades. We applied those metrics in a heuristic for cohort selection in a retrospective,
adjuvant endocrine therapy adherence study. Then, we generalized our heuristic so it may
be applied to a multitude of retrospective studies requiring longitudinal medical data. From
our study, we found several opportunities and limitations in applying longitudinal EHR data
to retrospective studies.
Data population in the EHR at Vanderbilt University Medical Center has been growing
since implementation due to increased functionality of the EHR, improved documentation,
and growing number of patients seen at the medical center. Differences in EHR implemen-
tation yield disparate availability for data-types over time. For instance, in breast cancer
patients, billing code data reaches 90% population at an earlier year than medication data
(year 1998, column Y0 for billing code data (Figure 3.3) and year 2000, column Y0 for
medication event data (Figure 3.4)). Learning when EHR data becomes consistently avail-
able allows cohort restriction for reliable data.
We found that data availability prior to breast cancer diagnosis (column Y-1, in Figure
3.3 and Figure 3.4) increases over time, but does not reach 90% population and may not be
sufficient for inclusion in longitudinal studies. Few data points for patients prior to a breast
cancer diagnosis is expected due to VUMC’s referral patterns.
We found that in some cases, a smaller percentage of patients had adjuvant endocrine
therapy medication events prior to their breast cancer diagnosis (column Y-1, Figure 3.5).
There are a few possible explanations for this: 1) They had DCIS (stage 0) non-invasive
breast cancer prior to their Stage I-III invasive breast cancer diagnosis are were receiving
risk reducing endocrine therapy, 2) The patient never had breast cancer but was at high
risk for getting breast cancer and was on risk reducing endocrine therapy, or 3) the NLP
algorithm extracted the information in error. We also found that many patients had more
than five years of adjuvant endocrine therapy medication events. This could be due to
1) clinical trials open to VUMC patients that extend adjuvant endocrine therapy, or 2)
patients with locally recurrent or metastatic recurrent disease receiving endocrine therapy
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for a different indication.
Through applying our cohort selection heuristic to adjuvant endocrine therapy patients,
we determined upper and lower bound adherence rates at each year for five years. At the
end of five years, adjuvant endocrine therapy adherence falls between 55% and 78% for
patients treated at VUMC. Our heuristic yields higher higher rates of adherence than a
previous retrospective study using EHR data without data availability metrics (49%) [55]
and lower rates of adherence than recent clinical trials (85%) [15].
The major contribution of this work is that it shows the impact of data availability on
secondary use of EHR data in retrospective studies. Missing data is the main contributing
factor to the wide range of adherence rates. VUMC’s EHR lacks follow up information
for 23% (78% adherence rate - 55% adherence rate) of stage I-III breast cancer patients
over a five-year time frame. While missing data may always be a challenge in retrospective
studies, improved communication to managing healthcare systems and improved documen-
tation in the EHR can reduce missing data in future time points.
Our generalized heuristic extracted from the methods and findings in this study can fa-
cilitate cohort creation for retrospective studies using longitudinal EHR data. Longitudinal
EHR data is a valuable basis for retrospective studies provided that the limits of the data
are investigated.
3.7 Limitations
This study is limited by the data captured in the Electronic Health Record system and
VUMC. Patient loss in the system is not reported in the EHR. When a patient no longer has
data in the EHR, it can be due to 1) an unreported death, or 2) discontinued care at VUMC.
In the second event, it is unclear whether the patient is receiving care in a non-VUMC
system or whether they have ended treatment. Additional datasets can help enrich this
study and better understand the patient’s state. Health plan datasets and additional health
information exchange can clarify patient loss in the VUMC system and allow for improved
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measures of adjuvant endocrine therapy adherence.
This work could further determine availability of patient death records by comparison
to the National Death Registry. Bridging to an external dataset in this case is challenging
because our data source was de-identified health records, which do not map to external
datasets. In different cases with identified data, there is potential to map to other datasets
and improve these methods.
3.8 Aim 1 Conclusions
This study describes metrics for data availability among adjuvant endocrine therapy pa-
tients treated at Vanderbilt University Medical Center. We measure the rise of data popula-
tion as VUMC’s EHR evolves, data persistence over time, and strategies to handle missing
data. Additionally, we generalize our methods for applications of EHR data extraction in
other healthcare domains. Application of these metrics facilitated cohort selection for a
longitudinal study on adjuvant endocrine therapy follow-up. We show the impact of data
sufficiency on secondary use of EHR data in retrospective studies and contribute general-
ized methods for cohort selection based of EHR data sufficiency.
The main findings of the study include:
• Data sufficiency can drive data selection for secondary use studies
• Data sufficiency metrics can serve as weights for missing data points
• Data sufficiency affects secondary use study results
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Chapter 4
Aim 2: Characterize the State of Patient Care
4.1 Overview
This chapter aims to characterize the state of patient care using Electronic Health
Record data. The text is an extended version of an academic article titled Analysis of
Adjuvant Endocrine Therapy from Breast Cancer Patient EHR Data and published by JCO
Clinical Cancer Informatics. The article defines the states of adjuvant endocrine therapy,
which include receiving patient care at VUMC, receiving care outside of VUMC, discon-
tinuing care, or death. We measure patient inclusion in states within the VUMC system,
and discusses the limitations of knowledge on patient states outside of the VUMC system.
We measure hallmarks of adjuvant endocrine therapy including drug switches, drug dis-
continuation, recurrence and death - occurrences reported in clinical trials, but previously
unmeasured in a real-world patient population.
This chapter shows the potential of electronic health record data to characterize the
state of patient care for adjuvant endocrine therapy patients. Additionally, this chapter
describes the limitations of electronic health records in characterizing the entirety of care
for a condition, and discusses generalizability for characterizing the state of patient care
in other healthcare domains. the main conclusions of the paper are 1) 49% of VUMC
adjuvant endocrine therapy patients were lost to follow-up or did not complete adjuvant
treatment throughout five years, 2) 52% percent of VUMC patients switched to a different
endocrine therapy drug during their treatment, and 3) VUMC’s EHR is a valuable resource
for characterizing the state of adjuvant endocrine therapy for VUMC patients.
36
4.2 Introduction
Adjuvant endocrine therapy is prescribed to hormone receptor positive breast cancer
patients for recurrence prevention post surgery. Clinical guidelines recommend patients
use adjuvant endocrine drugs for a five-year duration, with recent guidelines extending the
recommendation to ten years for some high-risk patient populations [14]. In this timeframe,
patients may deviate from their original treatment plan in the form of a drug switch or
termination [54]. Although clinical trials report rates of drug switches and termination
[15], the prevalence and motivations for these events in the general breast cancer patient
population are unmeasured.
There are several reasons a patient may change their adjuvant endocrine therapy treat-
ment. A drug switch may result from a change in menopausal status, intolerable side
effects, tumor recurrence, generic drug alternatives, or physician preference. Drug dis-
continuation may result from intolerable side effects, financial factors, or death. Measuring
rates of drug switches, termination, and their possible cause in patients in the general breast
cancer population yields an empirical projection for treatment strategies and outcomes.
Electronic health record systems (EHRs) store patient medical data including medica-
tions, billing codes, and diagnoses. EHRs allow for mining large quantities of adjuvant
endocrine treatment data to determine treatment trends over time. To understand treatment
patterns for adjuvant endocrine therapy in the general patient population, we analyzed Van-
derbilt University Medical Center’s (VUMC) EHR data for 1,587 stage I-III breast cancer
patients. Treatment data includes adjuvant endocrine therapy drugs taken by the patient,
timestamps for each drug, and ICD9 codes. Our goals are to 1) determine the frequen-
cies of drug switches and discontinuation, and 2) determine the potential cause for drug
switches and discontinuation. This study describes long-term adjuvant endocrine treatment
in real-world settings, and demonstrates the ability to use electronic health record data to
characterize oral medication treatment patterns in patients with cancer.
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4.3 Background
Hormone receptor-positive (HR+) breast cancers make up 70% of breast cancers [31]
and can be treated by preventing cells from taking in estrogen. Endocrine therapy interferes
with estrogen intake, and is prescribed as a neoadjuvant treatment to shrink HR+ tumors
prior to surgery. More commonly, endocrine therapy is prescribed as an adjuvant treatment
to prevent cancer recurrence post-surgery. There are several classes of adjuvant endocrine
therapy drugs, and they prevent estrogen intake by different mechanisms.
Selective estrogen-receptive modulators (SERMs) bind to estrogen receptors on cells
and make them unreceptive to extracellular estrogen. SERMs do not lower the overall
levels of estrogen in the body, therefore are prescribed to pre- and peri- menopausal women.
Potential side effects of SERMs include but are not limited to hot flashes, and increased risk
of blood clots, cataracts, and uterine cancer. In the ATAC adjuvant trial, approximately 40%
of patients on SERMs reported hot flashes [15].
Aromatase inhibitors (AIs) prevent aromatase enzymes from converting androgen into
estrogen, which lowers the amount of estrogen in the body. AIs are effective when a pa-
tient’s main source of estrogen is androgen conversion, a characteristic of post-menopausal
women. Pre- and peri-menopausal woman must undergo natural or artificial menopause in
order for AIs to be effective.
There are two types of AIs: steroidal and non-steroidal. Steroidal AIs form non-
reversible bonds with aromatase enzymes, while non-steroidal AIs form reversible bonds
and actively compete with androgen at binding sites. There is a lack of clinical trials fo-
cused on efficacy differences between steroidal and non-steroidal AIs, but because steroidal
AIs are purported to have androgenic effects, non-steroidal AIs are the recommended first
line AI treatment [33]. A common side effect of AIs is arthritis. A study by Henry et al
reported that out of a 97 breast cancer patients taking AIs, 44 experienced musculoskeletal
side effects, and 13 cases were severe enough for the patient to discontinue AI use [34].
Hot flashes, another common side effect of AIs, appeared in approximately 35% of patients
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on AIs in the ATAC adjuvant trial [15].
In 1977, the FDA approved the first endocrine therapy, tamoxifen (a SERM), for use
in metastatic hormone receptor positive breast cancer. In 1990, tamoxifen was approved
for use in the treatment of early stage hormone receptor positive breast cancer [35]. It was
subsequently approved for use in prevention of breast cancer in 1998 and for treatment
of non-invasive ductal carcinoma in-situ (DCIS) in 2000. Clinical studies on tamoxifen
show that it consistently reduces risk for death and tumor recurrence in HR+ breast cancer
patients [36].
In 2002, the first aromatase inhibitor, anastrozole, was approved and demonstrated su-
periority over tamoxifen in the adjuvant treatment of post-menopausal woman with breast
cancer [15]. Subsequently, in 2005, letrozole and exemestane, two alternative aromatase
inhibitors, were also approved as adjuvant endocrine therapies in this setting.
In 1998, clinical guidelines recommended adjuvant endocrine therapy for a five year
duration [16]. Recent guidelines extended treatment duration up to ten years in at-risk
populations [14]. With extended timeframes for duration of treatment and the growing
number of available drug options, adjuvant endocrine therapy treatment paths can vary
across patients. Clinical trials report varying rates of drug termination (31-73%) [15][37],
rates of adverse events [34][38], and drug switches [39], but there is limited information on
adjuvant endocrine treatment in the general patient population.
Electronic health records (EHRs) contain patient medical information including med-
ication events and diagnoses. As of 2014, over 75% of hospitals in the United States use
at least a basic EHR [57], and that percentage is growing. EHR use benefits patients and
providers by facilitating clinical workflow and improving healthcare quality. Additionally,
EHRs benefit research in that the data stored in the EHR allows for empirical analyses of
practice patterns and clinical outcomes [58]. EHRs for breast cancer patients receiving ad-
juvant endocrine therapy provide data to characterize longitudinal treatment patterns and
changes.
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Vanderbilt University’s Synthetic Derivative is a data source that contains deidentified
health records from over 2 million patients [52]. MedEx, a natural language processing
method, identified over 400 million medication events from medication lists and clinical
notes in the Synthetic Derivative [4]. From these resources, patient diagnoses, medication
events, and International Classification of Disease codes (ICDs), along with their respec-
tive timestamps, form a basis for analyzing adjuvant endocrine therapy treatment in breast
cancer patients.
4.4 Methods
4.4.1 Data Collection
Our data source is de-identified electronic health records collected at VUMC as part of
the Synthetic Derivative. The patient cohort met the following criteria: 1) Patients were
diagnosed with stage I-III breast cancer, determined from the Vanderbilt tumor registry, 2)
Patients received one or more of the following adjuvant endocrine therapy drugs: Anastro-
zole/Arimidex, Exemestane/Aromasin, Letrozole/Femara, Tamoxifen/Nolvadex (described
in Table 4.1, and 3) Patient’s adjuvant endocrine therapy began between 1998 and 2011.
These date restrictions enforce that patients were 1) recommended five years of treatment
and 2) can have at least five years of follow-up data. This study was done with the approval
of Vanderbilt’s IRB 140691, type exempt.
Data used in the study are adjuvant endocrine therapy medication events, patient ICD9
codes, and their respective timestamps. Death and recurrence data were collected from
Vanderbilt’s Tumor Registry. We used minimum medication event dates for ’start’ times
(i.e. the earliest medication start time). ’Stop’ times are estimated at 6 months post the
maximum medication event date. These estimates are based on expected patient follow-up
every six months in the first five years after diagnosis. Patients do not take more than one
adjuvant endocrine therapy drug simultaneously, so we interpreted the presence of a new
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Table 4.1: List of the endocrine therapy drugs used by patients in the study.
Generic Name Other Names Drug Class Year of FDA
approval for
metastatic
therapy
Year of FDA
approval for
adjuvant ther-
apy
Anastrozole Arimidex Non-steroidal
AI
2000 2002
Exemestane Aromasin Steroidal AI 2005 2005
Letrozole Femara Non-steroidal
AI
2005 2005
endocrine therapy drug in a record as a switch to the new drug.
4.4.2 Population Overview
To review our patient population, we began by defining all-inclusive states of adjuvant
endocrine therapy treatment at VUMC including unknowns due to limitations on the data.
We calculated statistics for patient inclusion in each group, and on patients grouped by
five-year treatment completion status and switching status. We calculated outcomes of
completion, death, and recurrence to determine differences among the patient groups.
4.4.3 Treatment Trends
Changes in the adjuvant endocrine therapy drug market, and new adjuvant endocrine
therapy knowledge, leads to changes in treatment switch and stop frequencies over time.
To determine drug prescription trends, we extracted prescriptions for the selected adjuvant
endocrine therapy drugs and calculated prescription frequencies over time. We graphed
the results along with the percent of patients who switched or stopped drugs by year. We
hypothesized that as drug options rise, drug switch frequency increases and drug stop fre-
quency decreases.
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4.4.4 Identifying a Cause for Treatment Changes
We hypothesize that the two adjuvant endocrine drug classes, SERMs and AIs, in-
cite different stop and switch patterns due to properties of the drugs. We hypothesize
that switches from a SERM to an AI are most likely concomitant with changes in pre- or
peri-menopause to post-menopause status, since AIs are only effective in post-menopausal
women. Alternatively, we hypothesize that a switch from an AI is most likely concomi-
tant with drug toxicity, since patients beginning on AIs are post-menopausal and their
menopausal status will not change.
We explored causes for drug switches or discontinuation with computational chart re-
views. We performed a text search for the stem words ’stop,’ ’switch,’ ’complain,’ and
’discontinue’ in Health Plan clinical notes written within a month (before or after) of a pa-
tient’s treatment change. Next, we manually reviewed a random sample of notes containing
a search word for direct references to changes in adjuvant endocrine therapy.
To explore the likelihood that switches from SERMs are correlated with a change in
menopause status, we calculated the age distribution and p-values of patients on SERMs
and patients switching from SERMs. For comparison, we calculated the age distribution
and p-values for patients on AIs, and patients switching from AIs. We hypothesized that the
age of patients switching from a SERM is greater than the age of patients taking SERMs,
indicating that their age and menopause progression is correlated with switching. We also
checked for evidence of artificial postmenopause progression through 1) CPT codes for
oophorectomies prior to a switch from a SERM and 2) medication events for estrogen-
suppressing drugs Goserelin and Leuprorelin prior to a switch from a SERM. Patients
undergoing oophrectomies or taking estrogen-suppressing drugs become postmenopausal,
and will likely switch medications.
To explore the likelihood that switches or discontinuation from AIs are correlated with
toxicity, we probed for a correlation between switching/discontinuation and ICD codes for
hot flashes and arthritis pain. The targeted ICD9 codes are 714.*, 715.*, 716.*, 729.*,
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627.2, and 782.62. We compared the rate of ICD codes in patients that switch/stop during
treatment to the rate of ICD codes in patients that complete treatment with no change. ICD
codes must have occurred within a year before treatment change or completion to ensure
1) we compare equal timeframe across groups and 2) ICD codes are relevant to the current
treatment plan. We hypothesized that ICD prevalence for hot flashes and arthritis would
be higher in patients who switch/stop treatment, indicating adverse events as a reason for
change. Furthermore, we hypothesized that patients who stop/switch from AIs have higher
ICD rates than patients who stop/switch from SERMs since stop/switch from a SERM
may result from a different cause - menopause status. To determine significant differences
between ICD prevalence, we calculated Fisher’s Exact test P-values.
SERMs and AIs have different mechanisms of action, resulting in disparate rates of
toxicity, and disparate efficacy among age groups. Consequently, age-related and toxicity-
related reasons for change exhibit different distributions across the two drug classes. To
explore if changes in SERM and AI treatment occur at different times, we examined the
time until treatment change in both drug classes. Switch/stop from an AI due to adverse
events may be localized to a certain time of toxicity onset. Conversely, changes in treat-
ment due to menopause progression are not localized to a certain time since the change is
dependent on a patient’s age and estrogen levels. We tested these hypotheses by graphing
time until drug switch or discontinuation for patients on SERMs and AIs.
4.5 Results
4.5.1 Population Overview
The patient states for adjuvant endocrine therapy treatment at VUMC are illustrated in
Figure 4.1 and define knowns and unknowns due to nature of the data. Our study includes
1,587 stage I-III breast cancer patients taking adjuvant endocrine therapy drugs. The aver-
age age of patients at treatment start is 56.9 (12.3 standard deviation). The average number
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of unique endocrine therapy drugs per patient is 1.5 (0.7 standard deviation). Approxi-
mately 64% of patients continued care at Vanderbilt post five years of adjuvant endocrine
therapy treatment.
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Figure 4.1: Adjuvant endocrine therapy treatment states at Vanderbilt University Medical
Center. Highlights differentiate between the data that is included in the VUMC EHR, and
data that is excluded from the VUMC EHR but exists in health plan information and claims
data.
Table 4.3 illustrates our patient population broken down by 5-year completion status
and switch status and Table ?? includes p-values for inter-group comparisons of recurrence
and death rates. Data comparisons of patient grouped by switch-status and completion-
status are illustrated in Figure 4.2. We show that approximately 48% of our patient popu-
lation does not complete at least 5 years of endocrine therapy for a reason other than death,
and therefore may not achieve the lowest possible risk of recurrence. The probability of a
patient completing five years of therapy given that they switched drugs is 60%, while the
probability for a patient to complete five years given that they did not make a drug switch
is 37%. Patients in our population who completed at least five years of treatment recurred
at a rate of 3.4% and patients who did not complete five years of treatment recurred at a
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Table 4.3: Adjuvant endocrine therapy statistics grouped by completing five years of treatment, death, switching drugs, report of recur-
rence, and maintained visits to a Vanderbilt facility.
Patient
Category
Number of
Patients
Percentage
of Patients
Recurrences
before five
years
Percentage
of recur-
rences
Deaths
before five
years
Percentage
of deaths
Number
of patients
with Van-
derbilt
visits post
five years
Percentage
of patients
with Van-
derbilt
visits post
five years
Switch
before 5
years
Stop be-
fore 5
years
Yes Yes 334 21.0% 35 10.4% 10 2.9% 163 48.8%
Yes No 500 31.5% 19 3.8% 0 0.0% 383 76.6%
No Yes 469 29.5% 30 6.4% 26 5.5% 229 48.8%
No No 284 18.0% 8 2.8% 0 0.0% 232 81.7%
Total 1587 100.00% 92 5.8% 36 2.3% 1007 63.5%
rate of 8.0%.
subsectionTreatment Trends
Figure 4.3 shows the endocrine therapy prescription frequencies at VUMC with the
percentage of patients stopping or switching their drugs each year. The graphs reflect a rise
in aromatase inhibitors after 2004. The percent of patients stopping treatment decreases
over time, and the percent of patients switching drugs increases.
subsectionExploring Causes for Treatment Change
Of the 1,303 patients who switched or stopped adjuvant endocrine therapy prior to five
years, 383 (29%) had an instance of the selected stem words in their clinical notes near
the time of change. 120 (9%) possessed ’stop,’ 73 (6%) possessed ’switch,’ 298 (23%)
possessed ’complain,’ and 59 (5%) possessed ’discontinue.’ In a random selection of 100
patients with stem-word-positive notes, 16% possessed a documented cause for changes to
adjuvant endocrine therapy, 20% possessed documented stopping or switching without an
explicit cause, and in the remaining 64%, stem words did not reference adjuvant endocrine
therapy.
Table 4.4 shows the average age of switch from a SERM is higher than the average age
of patients on SERMs. In contrast, the average age of patients switching from AIs is less
than the average age of patients on AIs. The distributions support that patients switching
from SERMs to AIs may be attributed to change in postmenopausal status.
Out of the patients who switched from a SERM to an AI, 16.5% had a reported oophorec-
tomy through either a CPT code 58940 or 58720, or an ICD9 parent code of 65 before their
switch date. Additionally, 11.5% of patients switching from a SERM to and AI received
either Goserelin or Leuprorelin (estrogen-suppressing drugs that place a patient in a post-
menopausal state). All together, 28% of the patients who switched from a SERM to AI
underwent an artificial change to post-menopausal status.
Arthritis ICD rates in patients who stopped or switched drugs were 42% and 72%
greater than arthritis ICD rates for patients who completed treatment without a switch for
SERMs and AIs, respectively (14.2% and 30.6% compared to 10.0% and 22.0%). Hot
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flash ICD rates in patients who stopped or switched drugs were 46% and 39% greater than
hot flash ICD rates for patients who completed treatment without a switch for SERMs and
AIs, respectively (24.8% and 25.0% compared to 17.0% and 18.0%). Furthermore, patients
who stop or switch from an AI have approximately double the rate of arthritis ICD codes
of patients who stop or switch from a SERM (Table 4.5).
Figure 4.3a shows the time distributions for stop and switch from AIs and SERMs. All
drug change distributions peak within the first year of treatment. Switching and stopping
from and AI occurs within a localized time. Switching or stopping from a SERM has a
broad distribution.
Table 4.4: Age distributions for patient at the time of AI use, SERM use, a switch from
an AI, and a switch from a SERM. P-values measure differences between the distributions.
Significant differences are denoted with an asterisk.
Drug Event Average Standard
Deviation
Comparison
Group
Fisher’s Ex-
act Test
P-value
AI Use 64.1 10.1 AI Use vs
SERM Use
<0.001*
SERM Use 55.4 12.8 AI Use vs
AI Switch
<0.001*
Switch from
AI
57.4 12.2 SERM Use
vs SERM
Switch
<0.001*
Switch from
SERM
60 10.7 AI Switch
vs SERM
Switch
<0.001*
4.6 Discussion
With electronic health record data from a cohort of 1,587 stage I-III breast cancer pa-
tients receiving adjuvant endocrine therapy, we found that approximately 48% of patients
did not complete the recommended minimum of five years treatment, and 52% of patients
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Table 4.5: Prevalence of billing codes for adverse events in patients, and Fisher’s exact test
p-values to determine significant differences between prevalence. Patients are grouped by
drug class and change in original treatment plan. Significant differences are denoted with
an asterisk.
Patient
Group
Arthritis
Positive
(Percent)
Hot Flash
Positive
(Percent)
Comparison
Group
Fisher’s
Exact Test
P-value P-value
Arthritis Hot
Flashes
Completed
SERM
without
switch
10 17 Complete
AI vs SS
from AI
0.040* .062
Stop/Switch
(SS) from
SERM
14.2 24.8 Complete
SERM vs
SS from
SERM
0.694 0.037*
Completed
AI with-
out switch
22 18 SS from
AI vs
SS from
SERM
<0.001* 0.947
Stop/Switch
(SS) from
AI
30.6 25 Complete
AI vs
Complete
SERM
0.005* 0.874
switched to a different endocrine therapy drug during their treatment. Using ICD codes,
we found that patients who changed their adjuvant endocrine treatment experienced higher
rates of arthritis and hot flashes than other patients. Changes in treatment in patients on
SERMs follow menopause progression inferred through age, administration of estrogen-
suppressing drugs or surgeries. Additionally, switching treatment from an AI is likely to
occur at the beginning of treatment, while switching from a SERM, is not localized to a
treatment time.
Patients who switched drugs at some point during their treatment are more likely to
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Figure 4.2: Rates of completion from patients grouped by presence of a drug switch, and
rates of recurrence from patients grouped by five-year treatment completion. The center
circle represents the full patient cohort, and the marginal circles.
complete at least five years of adjuvant endocrine therapy (Figure 4.2). Switching drugs
may be an expedient that encourages patients to continue treatment, and the additional
treatment time due to the switch may benefit the patients. We support that patients who
complete at least five years of adjuvant endocrine therapy gain a lower rate of recurrence
(3.4% compared to 8.0%) (Figure 4.2). The recurrence rates fall within the confidence
interval of population recurrence rates reported for stage 1 breast cancer (95% CI = 3% to
15%) [59]
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(a) Frequencies by individual adjuvant endocrine therapy drug.
4.6.1 Treatment Trends
Endocrine therapy prescription changes at VUMC reflect a rise in options for patients,
and as a result, the percent of patients switching adjuvant endocrine drugs exceeds the
percent of patients stopping adjuvant endocrine therapy in 2004 (shown in Figure 4.3).
The option to switch between endocrine therapy drugs may encourage adherence to the
recommended treatment duration.
4.6.2 Identifying a Cause for Treatment Changes
From our computational and manual chart review, we estimate that 5% of patients have
a clearly documented cause for adjuvant endocrine therapy treatment change. When docu-
mentation on the cause of treatment change is sparse, inferring potential reasons for change
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(b) Frequencies by adjuvant endocrine therapy drug class.
Figure 4.3: Changes in adjuvant endocrine therapy prescription frequencies and percentage
of patients stopping or switching at Vanderbilt University Medical Center over time. AI
prescriptions frequencies increase and SERM prescriptions frequencies decrease.
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(a) Density plot of time patient’s spent on AIs prior to stopping or switching.
with EHR data-applied informatics methods is an alternative way to retrieve such informa-
tion, but presents many challenges.
The age distributions for patients at the time of a drug switch (Table 4.5) support that
switching from a SERM is related to age. The average age during a switch from a SERM
is higher than the average age of patients treated with SERMs. In contrast, patient age at
a switch from AIs is less than patient age during AI use. A switch from a SERM is more
likely related to age than a switch from an AI. Additionally, 4.4 shows that switching from
a SERM is not localized to a specific duration of treatment, while switching from an AI
is. Switches from an AI are more likely due to adverse events that manifest within a year
of treatment. For example, Henry et al measured that musculoskeletal symptoms from AI
use peaked within 6 months 9. Switches from a SERM are likely dependent on a patient’s
individual menopause progression and appear at any time during treatment.
Patients who stop or switch their treatment experience higher rates of arthritis and hot
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Figure 4.4: Density plots showing temporal trends in adjuvant endocrine therapy drug use,
switches, and discontinuations. AI switches are localized to the first year while SERM
switches and not localized to a specific time point
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flashes than patients who complete their treatment without changes. The highest rates of
arthritis occurred in patients who stopped or switched AI treatment. Patients who stopped
or switched either AI treatment or SERM treatment experience similar rates of hot flashes
but more than those who did not switch. Pervious studies report musculoskeletal side
effects at a rate of 44% [34], and 44-47% [60] and 23% [61], and hot flashes from AI use
occur at a rate of 30% [61] and 35% [15]. Our lower rates are due to the source of our
data - the ICD codes. ICD codes appear in the patient record if the provider considers the
symptom severe enough to bill for it or document it. A symptom may not be documented,
but that does not guarantee the symptom’s absence.
4.6.3 Generalizability to Other Healthcare Domains
The methodology used in this study comprised of building a state diagram, statistical
summarizations, t-tests, density measures, and visualization. Provided a similarly sufficient
dataset to the one extracted in this study, these methods could be useful in characterizing
the state of patient care in other healthcare domains beyond adjuvant endocrine therapy.
The methodology at hand applies to long-term patient care, due to measures over time.
Characterizing the state of patient care in a short-term setting, such as outpatient emergency
room visits, is limited by this methodology because of the lack of longitudinal data on
which to measure patient states. Characterizing the state of adjuvant endocrine therapy at
VUMC supports that our methods have potential use in alternative long-term healthcare
domains.
4.7 Limitations
This study is first limited by the completeness of EHR data. We show in Figure 4.1 the
extent to which VUMC EHR data captures data on adjuvant endocrine therapy patients.
Data outside the realm of VUMC is missing, limiting the extent of characterizing complete
adjuvant endocrine therapy care. This study could be enriched with additional datasets,
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mainly health plan data, that follows patients across all facilities in which they receive
care. These datasets would clarify the unknowns in adjuvant endocrine therapy treatment
outside of the VUMC system.
This study is also limited by the medication event extraction tool used to extract med-
ications and timestamps collected in the EHR. We depend on timestamps for adjuvant en-
docrine therapy ’start,’, ’stop,’ and ’switch’ dates. Timestamps may be incorrect when the
medication event extraction tool identifies medications in the patient note that the patient
is not currently using. Also, clinical notes may be erroneously copied forward leading
to over-projected dates for treatment stop. Further limitations in the data include under-
documented recurrence, death, and adverse symptoms. Recurrence and death may be
under-reported due to lack of follow-up with patients, and ICD codes for adverse symp-
toms may be under-documented since they are captured by billing codes and providers do
not always bill for them.
Last, although we can make inferences on a reason to stop or switch adjuvant en-
docrine therapy treatment, cause of treatment change is infrequently documented in physi-
cian notes, making validation difficult. In addition to change in menopause status, adverse
events, and recurrence, changes in treatment can be due to financial factors [62] or physi-
cian preference, neither of which are documented in the EHR.
4.8 Conclusions
This study demonstrates the ability to leverage longitudinal electronic health records to
characterize treatment trends and the state of patient care in a cohort of adjuvant endocrine
therapy patients. We support that EHR data are a source for real-world frequencies of
adjuvant endocrine therapy patient tumor recurrence, drug-switch, and drug-stop, as well
as a source for exploratory analyses on causes for treatment change. We defined the states
of patient care for adjuvant endocrine therapy at VUMC and estimated patient inclusion in
states using data recorded in the EHR.
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The main findings of the study include:
• 49% of VUMC adjuvant endocrine therapy patients were lost to follow-up or did not
complete adjuvant treatment throughout five years.
• 52% percent of VUMC patients switched to a different endocrine therapy drug during
their treatment.
• Age and adverse events are correlated with changes in adjuvant endocrine therapy.
• VUMC’s EHR is a valuable resource for characterizing the state of adjuvant en-
docrine therapy for VUMC patients.
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Chapter 5
Aim 3: Identify New Opportunities to Improve Patient Care
5.1 Overview
This chapter aims to identify new opportunities to improve patient care. In the previous
chapters, we find that adjuvant endocrine therapy patients often fail to follow-up at VUMC
for treatment for the recommended five-year duration. Reasons for this include transfer of
care to a non-VUMC provider, discontinuation of care, or unreported death in the VUMC
EHR. Although it is not always clear why a patient fails to follow-up, there are predictors
in the EHR data that assists in identifying follow-up status. Supervised machine learning
is a computational solution to identify predictors from large, labeled datasets. The follow-
ing text is an extended version of an intended academic article titled Supervised Machine
Learning to Predict Follow-Up Among Adjuvant Endocrine Therapy Patients, which aims
to identify predictors for follow-up in EHR data using machine learning methods. We build
machine learning classifiers to predict follow-up with appointments and medication events,
and construct predictors for follow-up using EHR derived, appointment, and demographic
features.
This chapter demonstrates the potential of machine learning techniques to identify new
opportunities for patient care improvement, specifically improving patient follow-up, using
electronic health record data. We find that random forests are useful models for predict-
ing follow-up, and identify features that differentiate patients that follow-up. The main
conclusions from this chapter are 1) VUMC adjuvant endocrine therapy follow-up can be
predicted with and AUC of 0.74 using supervised machine learning methods, 2) EHR data
from adjuvant endocrine therapy patients holds predictors for follow-up, and 3) supervised
machine learning is a useful method for learning new opportunities for improvement in
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patient care through EHR data
5.2 Introduction
Adjuvant endocrine therapy is prescribed to hormone receptor positive breast cancer
patients to prevent tumor recurrence [16] [14]. Clinical guidelines recommend patients
use adjuvant endocrine therapy drugs for at least five years to minimize recurrence risk.
However, long-term care can be onerous for patients. Adjuvant endocrine therapy patients
must follow-up with their physician every six months, and may suffer side effects from
their adjuvant endocrine drugs [54] [15]. As a result, patients may fail to follow-up with
their physician for the recommended time, which results in suboptimal care and higher risk
for tumor recurrences [? ].
There are several reasons a patient may fail to follow-up with their care provider: poor
communication between patient and provider, burdensome distance between the patient
and care facility, negative side effects that discourage continued treatment, etc. Identifying
controllable reasons for failure to follow-up can promote interventions that improve follow-
up rates. However, reasons for failing to follow-up are not reported by patients, making it
challenging to find controllable factors that can improve follow-up rates.
One predictor may be distance to the VUMC facility. Breast cancer patients are often
referred to VUMC for treatment and subsequently travel for care. VUMC is centrally
located and around 200 miles from the next nearest cancer center (Figure 5.1). Once a
patient begins adjuvant endocrine therapy, they may chose to transfer care to a primary
care provider within closer proximity to their home.
Although reasons for failure to follow-up are not always reported back to the care
provider, information in Electronic Health Records (EHRs) may act as predictors for fail-
ure to follow-up. This information includes demographics, appointment patterns, and other
treatment information. One method that can predict follow-up in EHR data is supervised
machine learning. Supervised machine learning builds a function from labeled data that can
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Figure 5.1: Map of Vanderbilt University Medical Center location and locations of nearest
cancer centers.
be generalized to additional data points. There are several methods of supervised machine
learning including random forest and neural networks.
Random forests are ensemble learning methods that classify data and identify predic-
tors for classes. Random forests achieve accurate prediction for tasks involving electronic
health record data including predicting risk in hypertension control [63] and predicting ad-
verse drug events [64]. Features of random forests include an ability to capture non-linear
relationships, interpretable models, and included feature selection, where features are se-
lected based on their ability to split data [40].
Neural networks are machine learning methods that combine logistic regressions to
classify data. Neural networks achieved accurate prediction from electronic health records
data on tasks including heart failure detection [65]. Features of neural networks include
the ability to capture complex, non-linear relationships. However, the complexity of neural
networks makes models difficult to describe.
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Supervised machine learning classifiers built with adjuvant endocrine therapy patient
EHR data to predict follow-up uncovers predictors that may facilitate interventions and im-
prove follow-up rates. Improving follow-up rates in the adjuvant endocrine therapy patient
population will reduce recurrence rates and ultimately improve patient care in the cohort.
This study demonstrates the ability to use EHR data to find opportunities for improvement
in patient care and guide clinical decision-making.
5.3 Background
Adjuvant endocrine therapy is prescribed to reduce risk of tumor recurrence in hormone
receptor positive breast cancer patients. In 1998, clinical guidelines recommended adjuvant
endocrine therapy for a five year duration 1, and recent guidelines extended treatment for
up to ten years in at-risk populations [14]. These guidelines require patients to follow-up
with their care providers long-term. Unfortunately, follow-up times often fall short of the
recommended duration [? ]. There are many reasons for failure to follow-up, and a reason
is not always reported to the care provider when a patient fails to follow-up. However,
predictors for failing to follow-up may be found in the medical documentation leading up
to the follow-up failure.
Electronic health records (EHRs) contain patient medical information including ap-
pointment times, clinical communications, medication events and diagnoses. Vanderbilt
University Medical Center (VUMC) holds EHRs on over 3 million patients, and has a tu-
mor registry with records on over 90,000 patient tumors linked to EHR records. VUMC
holds health records on 2900 stage I-III breast cancer patients with at least one adjuvant
endocrine therapy medication event. Furthermore, VUMCs appointment audit logs contain
appointment scheduling patterns, including appointment frequency and cancellation fre-
quency, on over 2 million patients, approximately 20,000 of which are prescribed adjuvant
endocrine therapy drugs. These resources form a basis for predicting follow-up among
adjuvant endocrine therapy breast cancer patients.
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Random forests are ensemble learning methods that can accomplish prediction tasks,
including those based on EHR data [64] [63] [66]. Benefits of random forests include high
accuracy [40], resistance to over-fitting [67], ability to capture non-linear relationships,
and estimates of feature importance in the classification. Limitations of random forests
include over-fitting when underlying decision trees are too large, and misleading feature
importance estimates if features are correlated [40]. Random forests can find predictors for
follow-up within electronic health record data from adjuvant endocrine therapy patients.
Learning predictors for follow-up can lead to interventions that improve follow-up rates,
lower recurrence rates, and ultimately improve patient care.
Neural networks are combinations of activation functions that yield a classification pre-
diction [68]. Neural networks have accomplished complex prediction tasks from hand-
writing and facial recognition [69] [70] to clinical predictions for mortality risk [71] and
decision support [72]. Benefits of neural networks include the ability to capture signals
from large noisy datasets. Neural networks are limited by the large amount of data points
necessary to train the models, and by the challenges for interpretation due to dependence
on complex combinations of features.
5.4 Methods
Our methods begin with a basic measure for follow-up prediction, and continues to
complex measures for follow-up with supervised machine learning. We measure the aver-
age distance between patient home address and VUMC for patients that continue follow-up
at VUMC, measured through consistent appointments with any VUMC provider, over five
years from adjuvant endocrine therapy start. Then, we plot the odds ratio for follow-up
against failure to follow-up against distance. Our supervised machine learning methods
include data collection, feature matrix construction, classifier construction, evaluation and
optimization. A workflow for our methods is illustrated is Figure 5.2.
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Figure 5.2: A workflow for our supervised machine learning classification methods. We
begin with data collection from electronic health records, tumor registry entries, and ap-
pointment logs. We build treatment, appointment, and demographic features from the data
and model them as a matrix with the outcome variable ’0’ for patients who fail to follow-up
for five years and ’1’ for patients who follow-up with their care providers for five years.
We train and test a random forest classifier, evaluate performance and optimize parameters
to achieve the highest prediction AUC.
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5.4.1 Data Collection
Our data source is electronic health records, tumor registry data, and appointment
records collected at VUMC. Additionally, we obtained zip code census data from a public
source, and medication classes from Unified Medical Language System’s RxNorm. We
selected a patient cohort based on the following restrictions: 1) stage I-III breast cancer
diagnosis, determined from the Vanderbilt tumor registry, 2) medication event for at least
one of the following adjuvant endocrine therapy drugs: Anastrozole/Arimidex, Exemes-
tane/Aromasin, Letrozole/Femara, Tamoxifen/Nolvadex, and 3) began adjuvant endocrine
therapy between 1998 and 2011. These date restrictions ensure that patients were recom-
mended five years of treatment and could have at least five years of follow-up data. This
study was done with the approval of Vanderbilt’s IRB 160839, type exempt.
5.4.2 Feature Matrix Construction
We extracted data from electronic health records, tumor registry entries, and appoint-
ment logs for each patient in the cohort to build features for a classification matrix. This
data includes all interactions with the VUMC system with any provider and any depart-
ment. Features are listed in Table 5.1. N-categorical features were split into n-1 binary
features. The matrix has both binary and normalized continuous feature types.
We built three different binary outcome variables to measure: 1) consistent, yearly ap-
pointments with any VUMC provider, 2) consistent, yearly appointments with a VUMC
oncologist, and 3) consistent yearly VUMC medication events for adjuvant endocrine ther-
apy drugs. Outcome variables two and three are subsets of outcome variable one. Outcome
one captures patients who may transfer follow-up appointments with a primary care physi-
cian. Outcome two captures patients who strictly see oncologists. Outcome three captures
patients who not only follow-up with their clinician, but complete their adjuvant endocrine
treatment. Figure 5.3 illustrates the follow-up measures. We used years +/- a 3 month buffer
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as appropriate intervals to confirm follow-up. Patients are recommended to follow-up every
six months, therefore patients appropriately following-up have, at minimum, data once per
year. Patients who had a recorded death in the tumor registry before five years from their
initial adjuvant endocrine therapy medication event were censored from the matrix.
Figure 5.3: Projected patient treatment at VUMC with a guide for follow-up measures and
data used for predictions.
5.4.3 Classifier Construction
We used the Python machine learning packages SciKitLearn [73] to build random for-
est classifiers, and Keras [74] with Theano [75] to build neural networks. We depended
on the Advanced Computing Center for Research and Education (ACCRE) at Vanderbilt
University, Nashville, TN for building models with GPUs. We built classifiers from EHR
data, appointment data, demographic data, and a combination of all three data types. Clas-
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sifiers make predictions from patient data at both the start of adjuvant endocrine therapy
and as treatment data accrues. For each classifier, we divided data into train and test data
sets, trained a classifier on the training set, and used the sequestered test data to test the
classifier’s performance.
5.4.4 Classifier Evaluation and Optimization
We evaluated model performance by measuring the area under the Receiver Operator
Characteristic curves (AUC). The area under the ROC curve measures the probability at
which the classifier, given a positive and negative class, will assign a higher value to the
positive class than the negative class. We used five-fold cross validation to train and test five
classifiers per set of parameters, then averaged the AUCs together as a final performance
measure.
To optimize our classifiers, we adjusted underlying parameters and reevaluated ROC
AUCs. The parameters we adjusted for random forest classifiers include the maximum
number of features (m) to search for the best split (m, log m, or square root of m), the max
depth of the underlying decision trees (1 to m), the minimum number of samples required
to split a node (1 to 10), and the split criteria for features (entropy/information gain or
gini/impurity). The parameters we adjusted for neural networks include the number of
hidden layers and number of nodes per layer. We built classifiers for each combination of
parameters and returned the model with the best AUC.
5.4.5 Temporal Classifier Construction
After building base models on data collected between breast cancer diagnosis and ad-
juvant endocrine therapy start, we introduced data from the first year of treatment to our
training data. We hypothesize that prediction power improves as treatment data accrues.
We built classifiers with additional training data derived from quarter-year increments of
treatment up to one year. We measured the change in AUC and changes in significant
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features over time.
5.5 Results
5.5.1 Data Collection
1455 VUMC patients met our cohort criteria for adjuvant endocrine therapy follow-up
prediction. 838, or 57% of patients followed-up for the recommended five-year duration
with any provider in the VUMC system. 748, or 51% followed-up with an oncologist, and
576 or 39% followed-up on adjuvant endocrine therapy medications. The data we extracted
for patients in our cohort include over 2 million medication events, 293,000 ICD codes,
193,000 appointment logs, and 3,257 clinical communications. Furthermore, patients had
home addresses in 700 different zip codes, from which we collected distance and census
information.
5.5.2 Distance Measures
Over time the average distance of patients continuing to follow-up at VUMC shrinks
while the average distance of patients discontinuing follow-up at VUMC grows 5.4. The
ratio of density curves for distance among patients that follow-up and fail to follow-up at
VUMC over five years. This curve shows the ratio of follow-up to no follow-up for a given
distance from VUMC 5.5. When a patient is located less than 50 miles away from VUMC,
the odds that they will complete five years of follow-up is 3:2. For patients living at least
200 miles from VUMC, the odds that they will complete five-years of follow-up is less than
2:3.
5.5.3 Feature Matrix Construction
Overall, we constructed 321 features for 1455 adjuvant endocrine therapy patients at
VUMC. 307 features were built from EHR data, 7 features were built on appointment
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Figure 5.4: Box Plot of the log-transformed miles to VUMC center in adjuvant endocrine
therapy patients as they follow-up, or do not follow-up with a VUMC provider across five
years from adjuvant endocrine therapy start.
log data, and 7 features were built on demographic data. The majority of features were
counts for treatment with specific providers and departments, and presence of CPT codes
in electronic health record data. Consequently, our feature matrix was sparse.
5.5.4 Supervised Machine Learning
Our best classifier predicted follow-up with any VUMC provider and used combined
EHR, appointment, and demographic features. This classifier yields an AUC of 0.74 (Fig-
ure 5.6). The top five significant features are 1) total medications count, 2) age at diagnosis,
3) median zip code income, 4) distance in miles, and 5) counts of ICD9 parent code 719
for unspecified joint disorders.
Classifiers built solely on demographic, appointment, and medical features had less
prediction power than combined features, but medical features yielded the most prediction
power. Significant features for each of the models are listed in Table 5.2. Furthermore, pre-
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Figure 5.5: Odds ratio for follow-up status (pos five-year follow-up : neg. five-year follow-
up) against distance to VUMC.
dictions for follow-up when follow-up was measured through oncologist appointments and
adjuvant endocrine therapy medications yielded less prediction power than when follow-up
was measured through appointments with any provider at VUMC (Figure 5.6).
When optimizing our random forest model, we found that the AUC increased as max
depth of underlying decision trees increased until stabilizing at max depth of 15. Therefore,
we may prune the model to include our 15 most significant features, i.e eliminate 306 out
of the 321 features, and maintain our predictive power. Altering the minimum number of
samples required to split a node did not appear to have a significant impact on AUCs. We
found that splitting nodes based on gini index rather than entropy, resulted in the higher
AUCs.
We found that our neural network models achieved stable AUCs with two hidden layers,
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each with a number of nodes half the number of features. However, the neural networks
under-performed compared to the random forest models. A meta analysis on the size of
our data set suggests that our cohort is not large enough to achieve the maximum predictive
power of a neural network. Neural network AUCs do not stabilize as our dataset size
reaches its maximum (Figure 5.7).
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Figure 5.6: AUC measures for random forest and neural network classifiers built with
demographic, appointment, medical features and all features combined. All classifiers are
built with data collected from the time of breast cancer diagnosis to the start of adjuvant
endocrine therapy.
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Table 5.2: Top three features from random forest classifiers built from EHR, appointment
log, and demographic data to predict five-year follow-up with any VUMC provider among
adjuvant endocrine therapy patients
Primary Feature Secondary Feature Tertiary Feature
EHR Derived Fea-
tures
Total medication
count
ICD9 719 - Unspec-
ified joint disorders
ICD9 715 - Os-
teoarthritis and al-
lied disorders
Appointment
Features
Average copay Average appoint-
ment duration
Percent no-shows
Demographic Fea-
tures
Age at diagnosis Median zip income Diagnosis year
Figure 5.7: Change in AUC as size of dataset increases. The random forest AUC con-
verges, indicating saturated data for prediction. The 2-layer neural network AUC does not
converge, indicating additional data is required to achieve the best possible AUC. The data
used in this classifier was collected between the date of diagnosis and adjuvant endocrine
therapy start. Follow-up was measures through consistent appointments with ant provider.
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5.5.5 Random Forest Temporal Classifiers
Predicting failure to follow-up in adjuvant endocrine therapy patients improves slightly
as subsequent data is collected from the patients. At the time of adjuvant endocrine therapy
start, the data available to predict failure to follow-up results in 0.74 AUC for random forest
classification. The AUC increases with additional data collected over time, and rises 11%
for follow-up predictions built from one year of treatment data (Figure 5.8). Additionally,
the top significant features for random forest classifiers change over time, indicating a rise
in important predictors as treatment data is collected (Table 5.3).
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Figure 5.8: AUC for classifiers predicting follow-up in adjuvant endocrine therapy patients
built with quarter year increments of data collected from treatment start. Each prediction
is for five-year follow-up and the prediction window decreases as data is gathered. The
outcome variable is consistent follow-up with any VUMC provider.
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Table 5.3: Top three significant features from classifiers built on data collected in treatment
timeframes with follow-up outcome as consistent appointments with any VUMC provider.
Treatment
Time
0 months 3 months 6 months 9 months 12 months
1st Feature Total med-
ications
count
Total med-
ications
count
Total med-
ications
count
Total med-
ications
count
Total med-
ications
count
2nd Feature Age at diag-
nosis
ICD9 709 -
Other disor-
ders of skin
and subcuta-
neous tissue
ICD9 709 -
Other disor-
ders of skin
and subcuta-
neous tissue
ICD9 611 -
Other disor-
ders of the
breast
ICD9 611 -
Other disor-
ders of the
breast
3rd Feature Median zip
income
ICD9 611 -
Other disor-
ders of the
breast
ICD9 611 -
Other disor-
ders of the
breast
ICD9 627 -
Menopausal
and post-
menopausal
disorders
ICD9 627 -
Menopausal
and post-
menopausal
disorders
5.6 Discussion
Adjuvant endocrine therapy patients often fail to follow-up with their care providers
for the recommended five-year time frame. Although reasons for failing to follow-up
are not always reported to the care provider, medical-related, appointment-related, and
demographic-related data stored in EHRs may hold predictors for follow-up. Learning
predictors for follow-up may allow for interventions that improve follow-up rates, reduce
recurrence rates, and ultimately improve patient care in the adjuvant endocrine therapy
population.
Distance to VUMC may predict follow-up among adjuvant endocrine therapy patients
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at VUMC, but there are many more factors that affect patient follow-up. Electronic Medical
Records collect a wide variety of patient data that hold additional predictors for follow-up.
Finding signals among the noise requires more complex methods than single measures.
We found that supervised machine learning is capable of predicting failure to follow-
up using data from an adjuvant endocrine therapy patient cohort. The best classifier is
a random forest, and incorporates medical-related, appointment-related, and demographic
related features. Out of the three feature-types, medical-related features derived from the
EHR are the most significant predictors for follow-up among adjuvant endocrine therapy
patients.
The top three significant features in a combined random forest classifier include total
number of medications, age at diagnosis, and median income in zip code. A high total
number of medications for a patient suggest that 1) the patient has multiple conditions and
2) the patient receives multi-faceted care at VUMC. Whether a patient is treated at VUMC
for other conditions may indicate that they are likely to follow-up at VUMC for their ad-
juvant endocrine therapy. Patient age may affect decision making for adjuvant endocrine
therapy treatment. Older patients may be less inclined to follow-up, while younger patients
may be more motivated to complete treatment. Last, median income for zip code suggests
that financial burdens impact patient’s follow-up rates.
Out of three measures for follow-up we found that consistent appointments with any
provider at VUMC yields the best predictive power. This follow-up measure identifies pa-
tients that are more likely to have a primary care physician at VUMC or are being treated
for other conditions at VUMC. Measuring follow-up through VUMC oncologist appoint-
ments excludes patients that transfer their adjuvant endocrine therapy to their primary care
physician. Predictions for follow-up measured by adjuvant endocrine therapy medications
were most difficult to predict, likely because of multiple reasons for follow-up failure by
this measure (i.e. transferring care outside of VUMC, discontinuing drugs due to side ef-
fects, or discontinuing drugs due to metastatic disease).
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Through training, testing and optimizing our classifiers, we found optimal conditions
to predict follow-up given our feature set. Meta analyses measuring AUCs as a function
of model complexity (tree depth in random forest and hidden layers in neural networks)
identify minimally complex models that best describe the data without over-fitting. Fur-
thermore, a meta analysis on dataset size identified a limitation in neural networks that did
not affect random forests. We support that our random forest model is a valid model for
predicting follow-up among adjuvant endocrine therapy patients.
Predicting follow-up in adjuvant endocrine therapy patients can be achieved with an
as early as the time of treatment start with an AUC of 0.74. Predictive power increases
as health data is collected from the patient throughout the first year of treatment. The
changes in significant features predicting follow-up over time indicate a rise in predictors
as treatment data as collected. At the time of treatment start, total number of medications is
the most significant feature. This is likely correlated with the amount of treatment patients
receive at VUMC. As treatment data is collected, we see that ICD9 codes for menopause
and breast disorder become significant features predicting follow-up, indicating that the
patient’s health has impact on follow-up time.
5.7 Limitations
This study has limitations in both the dataset and the methods. The dataset used in this
study is drawn from VUMC’s EHR, which is not complete healthcare data for patients.
Data applicable to the study, but unavailable for use, includes health plan data and claims
data that describe patient’s complete care rather than treatment received solely at VUMC.
We measured adverse symptoms through billing codes, a strategy that captures adverse
symptoms severe enough for a physician to bill. However, this approach can excludes
many other patient complaints that are not billed for. The study is also limited by the
medication even extraction tool used to identify patient current medications. This tool may
erroneously identify drugs that a clinician records in patient notes for alternative reasons as
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a drug the patient receives. Last, we assume that patients are adherent to the drugs reported
as medication event despite evidence of non-adherence in other patient populations [76]
[77].
We built a large feature matrix in which groups of features are likely to be correlated.
For example, patients with an ICD code for cardiovascular disease likely have VUMC car-
diologist appointments and likely have medication events for anticoagulants. Correlated
features in random forests distort feature importances, as importance is spread out across
the features. Determining groups of features within our feature matrix could alleviate this
limitation. Our feature matrix did not include enough rows for a neural network to achieve
the highest possible AUC. Supplementing out dataset with patient data from other health-
care centers would enrich our neural network classifier.
Last, there are more features that may predict follow-up that are not recorded as part
of healthcare data therefore were inaccessible for this study. These features may include
patient access to transportation and childcare, or patient flexibility in work schedule. So-
cioeconomic factors are shown to impact adherence to healthcare [78] [79], and would
enrich models for follow-up predictions among breast cancer patients and patient in other
healthcare domains.
5.8 Conclusions
We built a supervised machine learning classifier capable of predicting five-year follow-
up measured three ways among adjuvant endocrine patients using medical, appointment,
and demographic data recorded in EHRs. Our classifier supports that total medication count
at VUMC, which is a measure of amount of care received at VUMC, is the most significant
predictor for follow-up long-term. Furthermore, although follow-up may be predicted as
early as the start of adjuvant endocrine therapy, predictive power increases as treatment data
is collected throughout the first year of treatment. Learning predictors for follow-up can
facilitate interventions that improve follow-up rates, guide clinical decision-making, and
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ultimately improve patient care. This study shows that EHR data and supervised machine
learning are valuable resources for finding opportunities for improvement in patient care.
The main findings of the study include:
• VUMC adjuvant endocrine therapy follow-up can be predicted with and AUC of 0.74
using supervised machine learning methods
• EHR data from adjuvant endocrine therapy patients holds predictors for follow-up
• One significant predictor for adjuvant endocrine therapy follow-up at VUMC is the
total number of medications, a measure of illness and care received at VUMC
• Supervised machine learning is a useful method for learning new opportunities for
improvement in patient care through EHR data
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Table 5.1: Delineated list of EHR, appointment, and demographic features calculated for
each patient. These features are used in a random forest classifier to predict failure to
follow-up among adjuvant endocrine therapy patients.
EHR Derived Features
• Cancer stage
• Adjuvant endocrine therapy medication type (0/1 for each type)
• Non-adjuvant endocrine therapy medication classes (Derived from RxNorm, count
for each class)
• ICD Parent Codes (count)
• CPT Codes (count)
• Providers seen (count)
• Departments visited (count)
• Number of clinical communications
Appointment Features
• Referral (0/1)
• Percent of appointments scheduled at time of previous appointment
• Percent of appointments cancelled
• Percent no-shows
• Number of appointments scheduled
• Average time between appointments
• Average appointment duration
Demographic Features
• Patient Age
• Diagnosis year
• Insurance type (public/private)
• Average copay
• Distance to care facility in miles
• Median Income for zip code
• Percent of population filing taxes for zip code77
Chapter 6
Overarching Conclusions
This dissertation describes methods to learn the state of patient care and opportuni-
ties for improvement from electronic health record (EHR) data. We approached this task
through three aims: 1) measure the sufficiency of EHR patient data, 2) characterize the
state of patient care, and 3) identify opportunities for improvement in patient care. For
proof of concept, the methods were applied to a cohort of adjuvant endocrine therapy pa-
tients treated at VUMC. However, the methods were built to be generalizable to other
EHRs and other healthcare domains. Overall, this dissertation matches clinical datasets
with computational methods to derive new clinical knowledge.
The scope of this dissertation is breast cancer patients receiving adjuvant endocrine
therapy at VUMC. Adjuvant endocrine therapy is a long term treatment that is challeng-
ing to characterize in real-world settings due to the need for consistent longitudinal data.
Nevertheless, characterizing adjuvant endocrine therapy in practice benefits patients and
care providers by providing realistic expectations for treatment and guiding in treatment
planning. The scope of this work directly benefits the breast cancer clinicians and patients
at VUMC describing providing previously unmeasured clinical workflows.
Work for Aim 1 measured the sufficiency of EHR patient data for study of adjuvant
endocrine therapy at VUMC. Chapter 3 describes three tasks to satisfy the aim: 1) measure
data availability, 2) build metrics based on data availability to facilitate data selection, and
3) generalize the methodology for application in other health care domains. We learned
that 1) data sufficiency can drive data selection for secondary use studies. We depended on
the availability of different EHR datatypes to create adjuvant endocrine therapy cohorts. 2)
Data sufficiency metrics can serve as weights for missing data points. We weighted missing
data from adjuvant endocrine therapy patients to balance loss from the EHR system with
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discontinued treatment. 3) Data sufficiency affects secondary use study results. We mea-
sured adherence rates across adjuvant endocrine therapy patient cohorts built with different
data availability metrics and found varying results.
Work for Aim 2 characterized the state of patient care among adjuvant endocrine ther-
apy patients at VUMC. Chapter 4 describes three tasks to satisfy the aim: 1) define all
possible states of adjuvant endocrine therapy care, 2) determine patient inclusion in each
state from EHR data, and 3) build statistical and visualization methods to characterize pa-
tient care. We learned that 1) EHR data can determine the distribution of patient across
clinical workflows. We were able to estimate rates of drug switches, drug discontinuations,
recurrence and death among a adjuvant endocrine therapy patients at VUMC. 2) Despite
the limitation of including only healthcare administered within and EHR system, EHR data
are valuable resources for drawing information on the state of patient care. The informa-
tion on adjuvant endocrine therapy patients at VUMC is valuable to patients and providers
because it informs patients and facilitates treatment planning.
Work for Aim 3 identified opportunities for improvement in patient care among ad-
juvant endocrine therapy patients at VUMC. Chapter 5 describes three tasks to satisfy the
aim: 1) extract features with the potential to affect care outcomes from EHR data, 2) frame
a classification problem using features and labels from the data, and 3) apply machine
learning methods to predict clinical outcomes. We learned that 1) EHR data contains fea-
tures that can predict the clinical outcome of follow-up among adjuvant endocrine therapy
patients at VUMC and 2) supervised machine learning is an appropriate method to predict
follow-up with EHR data. A significant predictor for adjuvant endocrine therapy follow-up
at VUMC is the total number of medications, a measure of illness and care received at
VUMC. This predictor informs clinicians that patients that are less ill or receive the major-
ity of their care outside of VUMC are less likely to follow-up. To translate this predictor
into and opportunity to improve care, a provider can take steps to refer the patient to a
non-VUMC provider to make it easier to them for continue their treatment. Patients may
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be more likely to continue treatment when it is simple for them.
A consistent limitation in this work is the boundary of VUMC’s EHR data, which cap-
tures patient care only administered in the VUMC system. Although VUMC data covers
a large number of clinics, it is likely that many patients in our study sought health care
outside of the VUMC system. Consequently, our dataset fails to capture complete health
care data for our cohort, and has ambiguities in care. By supplementing our datasets with
health plan data, or additional public and private clinical datasets, we can achieve a more
complete trajectory of healthcare for patients. However, matching clinical datasets is chal-
lenging. With the necessity to protect patient privacy, patient identifiers are often unique
to systems and slows patient identifying and tracking [80] [81]. Nevertheless, matching
clinical datasets informs clinicians of complete patient care, and improves secondary use
studies like those described in this dissertation. Therefore, there is a drive for data stan-
dards, interoperability, and health information exchange. This study would benefit from
EHR data enriched with other public and private datasets like health plan data. Capturing
complete health data from patients would minimizes ambiguity and inconsistencies while
improving accuracy of these results.
6.1 Future Directions
In future work, this study would greatly benefit from 1) enrichment with additional
datasets, 2) testing the generalizability to other healthcare domains, and 3) implementing
an opportunity for improvement into practice.
Repeating these studies using a more enriched dataset would reduce ambiguities and
inconsistencies in the current results, and yield a more comprehensive understanding of
adjuvant endocrine therapy in and outside of VUMC. Additional datasets that would enrich
this work include datasets from alternative EHRs and health plan data. To use these addi-
tional datasets, we need to extract the datatypes necessary for our methods: medications,
billing codes, and appointment data. We would determine the sufficiency of the data with
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Table 6.1: Summary of conclusions from the dissertations divided into knowledge from conclusions and beliefs about the broader
applications.
Aim Knowledge Beliefs
1. Sufficiency of the data EHR data sufficiency impacts studies on
adjuvant endocrine therapy at VUMC by
driving cohort selection and serving as
weights for missing data.
Methodologies to determine data suffi-
ciency among adjuvant endocrine therapy
patients at VUMC are generalizable to sec-
ondary use studies in other healthcare do-
mains.
2. State of patient care The EHR is valuable data source for char-
acterizing VUMC adjuvant endocrine ther-
apy. We were able to estimate rates of
drug switches, drug discontinuation, ad-
verse symptoms and outcomes, using pa-
tient data.
The EHR is a valuable resource for charac-
terizing the state of patient care for health-
care domains beyond adjuvant endocrine
therapy.
3. Opportunities for improvement EHR data from adjuvant endocrine ther-
apy patients at VUMC holds predictors for
follow-up, and supervised machine learn-
ing is a useful tool to learn follow-up prob-
abilities.
EHR data matched with appropriate com-
putational methods is a useful approach
to identify opportunities for patient care
improvement across many healthcare do-
mains.
our methodology, which includes determining the start and end of data on patients. We
would then characterize the state of patient care. Health plan data is especially beneficial in
this task. Health plan data includes care received at any institution regardless of the EHR
system, and will include death. Complete healthcare data eliminates ambiguities that exist
when a patient receives care outside of a single EHR system. Identifying opportunities
for improvement would be simplified with enriched datasets. We predicted follow-up for
adjuvant endocrine therapy patients, but the cohort of patients that fail to follow-up is di-
verse. Patients that fail to follow-up include patients that continue care outside of VUMC,
patients that discontinue care, and patients that die. Distinguishing between patient groups
allows for more focused predictions. For example, rather than predict follow-up at VUMC,
we can predict discontinued care. Truly improved patient care extends beyond where the
patient follows-up for care.
In additional future work, we will test the extent of the methodology’s generalizability
to other healthcare domains and other EHR systems. Other healthcare domains that are
appropriate test cases for these methods are long-term treatments. Therefore, we could test
the methods on other neoplasms for chronic conditions such as diabetes or chronic heart
failure. We could also test the methods for short-term conditions to learn how the methods
may be adapted to characterize the state of patient care and opportunities for improvement
among short-term patients. Short-term care includes emergency room visits, flu or infec-
tions. To generalize to other EHR systems, we need access to other EHR datasets. We may
learn additional steps for data clean-up and standardization necessary for our methodology.
For example, EHRs implement functionality and update standards at different rates, so
data availability changes across EHRs. We may also explore the potential to match patients
across EHR datasets and gain a more complete outlook of care. This would be unnecessary
with health plan data, but valuable if only EHR data is accessible.
Applying the methods in this dissertation to other healthcare domains and other EHR
datasets would identify further opportunities and limitations, strengthen our findings, and
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make the methods comprehensive. The demand to draw new knowledge from clinical
data holds across all healthcare domains. Scientific methods to characterize the state of
patient care and identify opportunities for improvement from EHR data are proportionately
valuable to the number of healthcare domains in which they are applicable.
Last, opportunities for improvement identified through these methods can be imple-
mented into healthcare practice to determine efficacy in shifting distribution of patients
into optimal states. We found that patients that receive primary care at VUMC are more
likely to follow-up for adjuvant endocrine therapy at VUMC. To shift the distribution of
patients away from failure to follow-up at VUMC to follow-up at VUMC, we may alert
providers when a patient is less likely to follow-up. This could occur as a notification in
the EHR at the time of an appointment. Then, the provider may recommend a primary
care physician at VUMC so complete treatment is received at VUMC. Once this process
is implemented, we can measure the rate of follow-up over time. If the rate of follow-up
for adjuvant endocrine therapy at VUMC increases in relation to the historical follow-up
rate, than 1) we have successfully found an opportunity for improvement, and 2) acted on
it leading to an improvement in healthcare for adjuvant endocrine therapy patients.
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